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Abstract 
Reperfusion limits ischaemic tissue damage. Paradoxically, reperfusion can cause 
additional tissue injury and contribute to a composite phenomenon known as 
ischaemia reperfusion (IR) injury.  Therapeutic interventions aimed at reducing IR 
injury have the potential to improve outcomes in the management of ischaemic 
conditions. Protective procedures such as ischaemic preconditioning (IPC), 
ischaemic postconditioning (PostC), remote preconditioning (RIPC) and remote 
postconditioning (RPostC) have all been shown in animals and humans to be 
effective in reducing IR injury. Experiments in this thesis sought to determine 
tractable aspects of the mechanisms underlying these protective phenomena with a 
view to validating potential pharmacological targets in humans. IR induced 
endothelial dysfunction in the forearm of healthy volunteers was characterised by 
vascular ultrasound and venous occlusion plethysmography.  
IPC, PostC, RIPC and RPostC all protected against IR-induced endothelial 
dysfunction. Oral inorganic nitrates in the form of beetroot juice or potassium nitrate 
(KNO3) also protected against endothelial IR injury. The magnitude of protection 
from IR injury was similar.  
The mechanism of PostC was investigated in detail. Protection by PostC was 
blocked by glibenclamide, a non selective KATP channel blocker, suggesting that 
activation of these potassium channels was necessary for PostC-induced ischaemic 
protection. Selectivity of KATP channels was evident because glimepiride (a selective 
KATP channel blocker) did not affect the protective effect of PostC. A role for the 
mitochondrial permeability transition pore (mPTP) was suggested by the effect of 
ciclosporin (blocker of the mPTP) to mimic PostC-induced protection. These aspects 
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of the mechanism of PostC resemble previously identified mechanisms of IPC and 
RIPC in the human forearm.  
Studies were undertaken to explore the mechanism whereby protection spreads 
systemically. Systemic protection by RIPC from ischaemic injury to the endothelium 
was blocked by the opioid receptor antagonist, naloxone without any effect on 
protection conferred by IPC or RPostC These data implicate the opioid receptor 
pathway in the facilitation of RIPC, and is likely to involve a haematogenous 
mechanism. Conversely, the alpha adrenergic receptor antagonist phentolamine, 
blocked systemic protection from RPostC but had no effect on RIPC. This highlights 
a role of a component of the autonomic nervous system in the mediation of RPostC.  
Ischaemic protection in humans is mechanistically a complex process but results in 
this thesis contribute to the validation of pharmacological targets as a prelude to 
drug development. 
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1.1 Introduction 
Cardiovascular disease remains the major cause of death globally amounting to 17 
million deaths a year (1). Ischaemia accounts for the majority of these deaths and 
results from arterial occlusion mainly due to athero-thrombosis. Most commonly this 
presents clinically as coronary heart disease (CHD) and stroke which are projected 
to remain the leading causes of death worldwide over the next two decades (1). 
Timely reperfusion improves outcomes of CHD and stroke but paradoxically this 
causes an injury to tissues. The resulting injury is a composite of ischaemia and 
reperfusion – ischaemia-reperfusion (IR) injury. Reducing reperfusion injury might 
further improve the clinical effectiveness of existing reperfusion strategies.  
This thesis aims to use an in vivo model of IR injury in the human forearm to 
investigate the mechanisms of protective strategies against IR injury. These are 
postconditioning (PostC), remote preconditioning (RIPC), remote postconditioning 
(RPostC) and inorganic nitrate.  
 
1.2       Athero-thrombosis  
 
1.2.1 Definition and relevance to ischaemia 
Atherosclerosis is the most frequent underlying cause of human arterial thrombosis. 
It has been defined as “a multifocal, smouldering, immunoinflammatory disease of 
medium–sized and larger arteries fuelled by lipid” (2). This inflammatory process can 
ultimately lead to the development of complex lesions, or plaques, that protrude into 
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the arterial lumen and cause vascular obstruction and occlusion (3). This is 
manifested clinically as acute or chronic ischaemic syndromes involving the heart, 
brain, leg and other tissues. The main risk factors for the development of 
atherosclerosis are elevated plasma cholesterol, age, hypertension, diabetes, 
smoking and male gender (2). 
Pre-clinical atherosclerosis begins in early childhood and progresses during 
adolescence and adulthood (4, 5). In susceptible individuals under the influence of 
risk factors, clinical disease processes caused by atherogenesis become evident 
later in life.  
 
1.2.2 Pathology of atherosclerosis 
Arterial wall morphological changes, including thickening and reorganisation of the 
tunica intima, excess synthesis of collagenous matrix (fibroblastic intimal thickening) 
and permanent or dynamic deposition of lipids (fatty streaks) already occur in 
childhood or adolescence (6). A fatty streak is an accumulation of subendothelial 
lipid laden cells that are prevalent in young people and never cause symptoms (7, 
8).  In the presence of risk factors, endothelial dysfunction occurs and this is thought 
to be the promoter of the atherothrombotic disease process. 
Endothelial dysfunction and leakage of the endothelial barrier increases the 
expression of two classes of adhesion molecules, the selectins and the 
immunoglobulin gene superfamily [VCAM-1 and ICAM-1] (6, 9).  This leads to an 
accumulation of monocytes, T-lymphocytes and lipids in the subendothelial space 
where potential atherogenic lipoproteins are retained and modified to become 
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cytotoxic, proinflammatory, chemotaxic and proatherogenic (2, 6). The imbalance in 
lipoprotein influx and efflux, intraplaque haemorrhage and the development of the 
extracellular matrix promotes progression of early atherosclerotic lesions which are 
known as plaques (9). An advanced coronary plaque is composed of a necrotic lipid-
rich core and hypocellular fibrous cap (2). Rupture of the cap exposes the 
prothrombotic core to circulating blood and leads to vascular occlusion. 
Atherogenesis may have a genetic basis, making some individuals more susceptible 
to the effects of hyperlipidaemia (10). It has been proposed that microalbuminuria 
reflects a state of generalised transendothelial leakiness for plasma proteins, an 
important event in atherogenesis (10). Risk factor modification has an important 
influence on the progression of atherosclerotic disease, particularly blood pressure 
and cholesterol reduction.  
 
1.3 Ischaemia  
Ischaemia is the result of vascular occlusion and leads to deprivation of oxygen and 
nutrients in a tissue or organ. Research has focused mainly on myocardial 
ischaemia in view of its substantial impact on morbidity and mortality. The 
pathophysiologic mechanisms of ischaemia in the heart, however, also apply to 
other tissues and organs. 
Acute ischaemia is characterised by (a) cessation of aerobic metabolism, (b) 
depletion of creatine phosphate (high-energy phosphate), (c) onset of anaerobic 
glycolysis and (d) accumulation of glycolytic products such as lactate and catabolites 
of the nucleotide pools in tissues (11). These processes, which commence within 
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seconds of ischaemia, are consequent upon hypoxia and subsequent loss of aerobic 
adenosine triphosphate (ATP) production and if prolonged may lead to irreversible 
cell damage. The shift to an anaerobic source of ATP is compensatory but still only 
comprises about one fourth of the myocardial aerobic glycolytic rate which 
eventually ceases after about 60 minutes of ischaemia (11).  
 
1.3.1 ATP metabolism during ischaemia  
The high-energy bond of ATP is the main source of energy for myocardial function 
and ATP concentration has been identified as an important correlate of myocardial 
function following ischaemia (12, 13).  Reduction in oxidative phosphorylation 
through the citric acid cycle causes myocardial ATP levels to decrease progressively 
during ischaemia, resulting in decreasing levels of intracellular creatine phosphate 
and increasing levels of intracellular phosphate (demand for high energy phosphate 
exceeds supply) [Figure 1.1]. As the ATP is metabolised, adenosine diphosphate 
(ADP) begins to accumulate. ADP is in turn converted to ATP and adenosine 
monophosphate (AMP) by the action of adenylate kinase (11). The ATP formed from 
ADP by adenylate kinase is re-used as a source of energy while the AMP is 
converted to adenosine and inorganic phosphate (Pi) by 5’ nucleotidase (5’ND). The 
adenosine is deaminated to inosine via adenosine deaminase (14). Adenosine and 
inosine are nucleosides and in contrast to nucleotides, can diffuse from the myocyte 
to the extracellular space where the inosine is degraded to hypoxanthine and 
xanthine by the action of nucleoside phosphorylase and xanthine oxidase 
respectively (11). As the duration of ischaemia increases, further breakdown to 
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diffusable metabolites occurs resulting in decreasing levels of ADP and AMP which 
invariably affect supplementary ATP production (12). In addition, further oxidation of 
xanthine by xanthine oxidase is a source of generation of reactive oxygen species 
(ROS) (15, 16). Both processes may lead to cell death.  
 
Figure 1.1: Changes in ATP metabolism during ischaemia. Tissue hypoperfusion causes a reduction in 
oxidative phosphorylation which is the main cellular source of ATP (aerobic pathway). The cells resort to other 
sources of ATP (anaerobic pathway) which provide amounts of ATP insufficient for normal cellular function. If this 
process is prolonged irreversible cell damage will occur. (Adapted from Jennings RB, 1982) 
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1.3.2 Ionic homeostasis during ischaemia 
Energy supply in the ischaemic myocardium is determined by the rate of ATP 
generation and the declining tissue ATP concentration (rate of high energy 
phosphate utilisation, or demand) (11). With prolonged ischaemia, anaerobic 
metabolism leads to the abnormal accumulation of metabolites and lactic acid, a 
decrease in intracellular pH and K+ and an increase in intracellular Na+ and Ca2+.  
These changes are deleterious to myocardial function (15, 17).   
The reduction in intracellular pH activates the Na+/H+ exchanger in an attempt to 
restore the pHi. Together with  the reduction of ATP production and inhibition of the 
Na+/K+ -ATPase there is an increase in the intracellular Na+ , Cl- and water, which 
leads to cell swelling (15, 17). Inhibition of the Na+/Ca2+ exchanger and both 
sarcolemmal and plasmalemmal Ca2+ ATPases, which usually pump Ca2+ out of the 
cell, increases intracellular Ca2+ (18). This may result in activation of degradation 
enzymes such as phospholipases, proteases and nucleases that can lead to 
irreversible cell damage characterised by disruption of the plasma membrane (15, 
17) [Figure 1.2].  
 
1.3.3 Mitochondrial function during ischaemia 
Mitochondrial integrity is important in cell survival. An impermeable inner 
mitochondrial membrane is essential to maintain the membrane potential and pH 
gradient that enables ATP synthesis through oxidative phosphorylation. If the 
permeability barrier of the inner membrane is disrupted, mitochondria become 
uncoupled, and thus, can neither synthesise ATP by oxidative phosphorylation nor 
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separate cytosolic and mitochondrial pools of metabolites (15). These mitochondrial 
changes, which occur during ischaemia, have been attributed to an increase in 
intracellular phosphate and disruption in cell Ca2+ homeostasis and may ultimately 
lead to cell death (15, 19). 
 
1.3.4 Vascular injury during ischaemia 
Endothelial cells maintain vascular homeostasis and are vulnerable to ischaemic 
damage.  Prolonged hypoxia reduces endothelial cell production of certain bioactive 
agents (prostacyclin, nitric oxide) and stimulates the production of other agents 
(endothelin, thromboxane A2) (20). However, overt microvascular damage in the 
myocardium does not appear until after 60 minutes or more of severe in vivo 
ischaemia, at which time endothelial disruption is believed to contribute to 
microvascular obstruction. (11). 
 
1.3.5 Irreversible ischaemic injury  
The hallmarks of early phase irreversible injury include: a) ATP<10% of control; b) 
high concentrations of H+, AMP, inosine, and hypoxanthine; c)  cessation of  
anaerobic glycolysis; d) high lactate and low glycogen; e) mitochondrial swelling with 
amorphous matrix densities and f) focally disrupted sarcolemma which seems to be 
the final event (11).  Reperfusion prevents progression from reversible to irreversible 
injury by restoration of oxidative phosphorylation and washout of harmful metabolites 
of glycolysis such as lactate. 
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Figure 1.2: Cellular ionic homeostasis during ischaemia. Tissue hypoperfusion results in untilisation of 
anaerobic sources of ATP production. The formation of acidic cellular metabolites leads to a disruption of ionic 
homeostasis which is deleterious to cellular membrane integrity. This culminates in cellular injury and death. 
(Adapted from Buja LM, 2005) 
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1.4 Reperfusion injury 
Reperfusion is essential for tissue salvage but paradoxically has deleterious effects 
on tissues. Reperfusion injury does not occur independently of ischaemia and this 
composite is often referred to as ischaemia-reperfusion (IR) injury.  
A period of prolonged ischaemia causes the cells to resort to the glycolytic source of 
ATP production. This pathway does not provide sufficient amounts of ATP. 
Furthermore, the anaerobic state leads to the accumulation of lactic acid,   a 
decrease of the intracellular pH, and an increase in intracellular Na+ concentration. 
Further depletion of ATP leads to dysfunction of the Na+/K+ -ATPase which causes a 
reversal of the Na+/Ca2+ antiporter and intracellular Ca2+ overload. The details of this 
process have been discussed above. With reperfusion the resupply of oxygen 
causes an abundance of oxygen free radicals which in combination with intracellular 
Ca2+ overload have a deleterious effect on cellular function. The duration of 
ischaemia correlates with the amount of tissue damage and without reperfusion 
there will be no tissue salvage. However, timely reperfusion of salvageable tissue 
may itself account for up to 50% of the final myocardial infarct size in experimental 
studies (21).  
 
1.4.1 Mechanism of reperfusion injury 
Recent research has demonstrated a key role for mitochondria as an end effector in 
the mechanism of IR injury.  Myocardial reperfusion leads to a number changes 
which include: the generation of reactive oxygen species (ROS), intracellular calcium 
overload, the rapid restoration of physiologic pH, and inflammation (21). These 
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changes lead to disruption of mitochondrial membranes (permeabilisation) which 
plays a crucial role in cell death (15, 22 - 24).  
Cell death may occur via a variety of pathways. Apoptosis is a programmed cell 
death and results from permeabilisation of the outer mitochondrial membrane 
(OMM) which leads to release of cytochrome c and other pro-apoptotic factors (25, 
26). The details of this process remain unclear but it is thought to be a cause of 
naturally occurring cell death in response to developmental, homeostatic or internal 
damage signals. Autophagy occurs in cellular nutrient deprivation and entails 
recruitment of proteins such as p19ARF to the mitochondria predisposing them to 
engulfment by autophagic vacuoles and transfer to lysosomes (26). The process of 
necrosis involves opening of the non-specific pore in the inner mitochondrial 
membrane (IMM), known as the mitochondrial permeability transition pore (mPTP) 
(25, 26) [Figure 1.3]. Necrosis results from deleterious cellular conditions such as 
the presence of toxins or during reperfusion injury. 
 
1.4.2 The mitochondrial permeability transition pore 
The mPTP is a non-specific pore in the inner mitochondrial membrane that normally 
remains closed but under conditions of cellular stress can open and lead to cell 
death. There are two major consequences of opening of the pore (24): a) There is 
free passage of molecules of <1.5kDa across the inner mitochondrial membrane, but 
not proteins. This creates a colloidal osmotic pressure that causes the mitochondria 
to swell and eventually there is rupture of the outer membrane leading to release of 
proteins such as cytochrome c into the intermembrane space. The result is cell 
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death. b) The inner membrane becomes freely permeable to protons and this 
uncouples oxidative phosphorylation. The resulting depletion of intracellular ATP 
levels leads to disruption of ionic and metabolic homeostasis and activation of 
degradation enzymes. If pore closure does not occur then these changes will lead to 
irreversible cell damage (22-24).  
The exact molecular structure of the mPTP is not yet known, but it is thought to 
comprise two candidate proteins - adenine nucleotide translocase (ANT) and the 
mitochondrial phosphate carrier (PiC) which occur in abundance in the IMM and are 
susceptible to damage by oxidant stress (26).  Another mitochondrial protein known 
as cyclophilin D (Cyp-D) possesses peptidyl-propyl cis-trans isomerase (PPIase) 
activity and binds to PiC under the influence of increasing Ca2+ concentration and 
oxidative stress.   This leads to a conformational change in either PiC or ANT that 
promotes pore formation/opening (24, 26) [Figure 1.4]. Evidence of a role for Cyp-D 
in pore formation is supported by studies in which pharmacological inhibition or 
genetic ablation of Cyp-D conferred resistance to acute IR injury (24, 27-31).  By 
preventing Cyp-D binding to PiC or ANT, ciclosporin acts as a potent inhibitor of the 
mPTP. Another potent inhibitor of the mPTP is Sangliferin A (SfA), which inhibits 
PPIase activity (24). Other proteins thought to be implicated in mPTP formation 
include the voltage dependent anion channel (VDAC), the peripheral 
benzodiazepine receptor (PBDR), hexokinase, and Bcl-2, but their role is not well 
defined (26). Experimental evidence indicates that the mPTP is closed during 
ischaemia and only opens during reperfusion (32). This makes the early phase of 
reperfusion an attractive therapeutic target. 
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Figure 1.3: mPTP: the final common pathway of reperfusion injury. With reperfusion, the rapid 
replacement of oxygen causes mitochondrial re-energisation which leads to generation of ROS, a further 
increase in intracellular calcium concentration (due to a combination of dysfunction of the sarcoplasmic reticulum 
calcium uptake mechanism and rapid restoration of the Na+/Ca2+ exchanger activity) and a reduction in pH. 
These processes lead to opening of the mPTP resulting in cell death.   
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Figure 1.4: A proposed working model of the mPTP (26). 
 
1.4.3 Reactive oxygen species  
Free radicals are molecules that contain one or more unpaired electrons and so are 
chemically reactive. Oxygen free radicals are formed continuously in minute 
quantities during normal metabolism of mammalian cells and these are inactivated 
by free radical scavenging systems such as superoxide dismutase, catalase and 
glutathione peroxidase (33-35).  During IR injury increased production overwhelms 
these protective mechanisms, and increased concentration can be detected by using 
chemiluminescence, fluorescent detection and electron paramagnetic resonance 
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spectroscopy (36-38).  In addition, the reduction of IR injury by ROS scavengers in 
experimental models implicates their role in IR injury (39-42).  
ROS generation in reperfused myocardium occurs within the endothelial cells and 
myocytes. Enzymatic sources include activation of leucocyte NADPH oxidase, 
xanthine oxidase, mitochondrial oxidative phosphorylation, cycloxygenase mediated 
unsaturated fatty acid oxidation, catecholamine oxidation, P450-mediated oxidation, 
uncoupling of eNOS, and iron release and redox cycling (43, 44).  The overall 
burden of oxidative stress is further exacerbated by chemotaxis of leucocytes 
resulting from ROS produced by endothelial cells and myocytes. 
NADPH oxidase (also called Nox) is a major source of superoxide and is found 
mainly in phagocytes (neutrophils, eosinophils, monocytes and macrophages) (45). 
The enzyme is inactive in resting phagocytes but is activated by contact with 
microbes or inflammatory mediators (45, 46). Structurally, NADPH oxidase consists 
of the membrane bound catalytic subunit (Nox 1 – 5) that transfers electrons from 
NADPH to molecular oxygen to form superoxide, a smaller membrane-bound protein 
(p22phox) that stabilizes the Nox subunit within the membrane and cytosolic 
regulatory subunits – p47phox, p40phox, p67phox and GTPase RAC (45, 46).  
IR injury results in neutrophil activation which promotes NADPH oxidase activity and 
increased ROS production (47). The role of NADPH oxidase in the pathophysiology 
of IR injury is suggested by upregulation of Nox 2 in ischaemic human 
cardiomyocytes (48) and protection against IR injury in NADPH oxidase knockout 
mice in a variety of organs (49-52).  These findings are supported by evidence from 
a recent study, using a human in vivo model of IR injury.  Patients with chronic 
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granulomatous disease who have mutations in genes encoding for specific NADPH 
oxidase with disruption of oxidase activity, exhibit reduced endothelial IR injury (53).  
Xanthine oxidoreductase is an another important contributor to the total cellular ROS 
load and exists in two interconvertible forms – xanthine dehydrogenase (XDH) and 
xanthine oxidase (XO), both of which catalyse the conversion of hypoxanthine and 
xanthine (54).  XDH utilises mainly NAD+ to accept electrons yielding NADH and uric 
acid whereas XO has a greater affinity for oxygen forming superoxide and hydrogen 
peroxide. The relative availability of these two forms is therefore important in 
determining the amount of ROS produced by these enzymes.  
ROS are therefore recognised to contribute to cell death during IR injury in 
experimental studies using animal and human models of IR injury. However, 
reducing ROS activity has proved to be an intractable therapeutic target to date. A 
number of clinical studies of antioxidants in acute ischaemia have demonstrated a 
null therapeutic effect (55). The reasons for this might be variability in clinical 
characteristics, dose and timing of interventions in experimental and clinical studies. 
 
1.4.4 Neutrophil activation 
IR injury activates the innate immune mechanisms to induce an inflammatory 
reaction by increasing the expression of cytokines (TNF, IL-1β, IL-6, IL-8), 
complement fragments (C5a), ROS, leukotriene B4, thromboxane A2, platelet 
activation factor, ICAM and P-selectin (56). This promotes chemotactic recruitment 
of neutrophils and their adhesion to the endothelium. This causes occlusion of the 
microvasculature and the release of neutrophil-derived mediators of IR injury 
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(proteolytic enzymes, ROS, CD 11/CD18). Evidence for a pathogenic role for 
neutrophils during IR injury is mainly from animal studies in which protection against 
IR injury was achieved with neutrophil depletion or specific blockade of neutrophil 
adhesion molecules (57-61).  
However, the significance of neutrophil activation remains contentious given that IR 
injury occurs in neutrophil-free systems such as isolated heart preparations (56). In 
addition, results from clinical studies of anti-neutrophil and anti-inflammatory 
therapies have not been successful in reducing IR injury (55, 56).  
 
1.5 IR injury and the vasculature  
Vascular endothelial cells appear to be particularly susceptible to injury as a result of 
both ischaemia and reperfusion. This manifests as endothelial dysfunction that 
affects the arterioles, capillaries and venules (20).  
 
1.5.1 Physiology of endothelium 
The endothelium is a single layer of cells that lines the inner surface of blood 
vessels. They were initially thought to be inert, acting as a barrier between blood and 
vascular smooth muscle. However, vascular endothelial cells have been 
demonstrated to possess paracrine functions which regulate a number of vascular 
processes including vascular tone, cell adhesiveness and coagulation (62). The 
endothelial effect on blood vessel function is achieved by the local production of 
vasodilators (NO, prostacyclin and endothelium derived hyperpolarisation factor, 
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EDHF) and vasoconstrictors (thromboxane and endothelin) (62). During normal 
vascular function the endothelial release of vasodilators predominates and any 
changes in this balance may lead to altered vascular tone. The release of 
vasodilators by endothelial cells can be potentiated by a number of chemical 
agonists (acetylcholine, substance P, bradykinin) and physical factors such as sheer 
stress generated by an increased blood flow. 
 
1.5.2 Endothelial mediators 
Furchgott and Zawadzki demonstrated that vascular smooth muscle relaxation 
occurred in response to acetylcholine and this was dependent on an intact 
endothelial layer (63). They named the mediator responsible for this effect 
endothelium derived relaxing factor (EDRF) and this was later identified as NO. 
NO is a free radical gas derived in the endothelium mainly by the conversion of the 
precursor amino acid L-arginine in the presence of molecular oxygen and co-factors 
such as BH4, NADPH and flavin adenine dinucleotide (FAD) (64). This process is 
catalysed by the constitutively expressed endothelial nitric oxide synthase (eNOS). 
However other isoforms of NOS may contribute to NO bioavailability and include 
neuronal (n) NOS and inducible (i) NOS. The nomenclature for the NOS isoforms 
reflects the tissues of origin for the original protein and DNA isolates and their level 
of expression might vary under different physiological conditions (64, 65). NO is 
freely diffusible and its vasodilator properties of NO arise from its effect on vascular 
smooth muscle cells by activating soluble guanylate cyclase (sGC). This leads to 
increased production of cyclic 3’,5’ guanosine monophosphate (cGMP) and a 
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reduction in intra-cellular calcium within the smooth muscle cell, causing smooth 
muscle relaxation (66).  The biosynthesis of NO is regulated by endogenous NOS 
inhibitors [asymmetrical dimethylarginine (ADMA) and NG-monomethyl-L-arginine 
(L-NMMA)]. An alternative pathway of NO generation (endothelium independent), 
thought to be activated during ischaemia, will be discussed in section 1.10 of chapter 
1 of this thesis. 
Prostacyclin and thromboxane A2 are endothelium derived molecules synthesized 
from the precursor compound arachidonic acid (AA) which is released from cell 
membrane phospholipids (67, 68). Cyclo-oxygenases (constitutive COX-1 and 
inducible COX-2) act on AA to generate prostaglandin endoperoxides which are the 
substrate for prostacyclin and thromboxane synthases (67, 68). Prostacyclin causes 
vasodilatation via activation of adenylate cyclase leading to increased levels of cyclic 
adenosine monophosphate (cAMP) which causes smooth muscle relaxation. 
Furthermore, prostacyclin is a potent inhibitor of platelet aggregation. Thromboxane 
A2, on the other hand, produces vasoconstriction by causing smooth muscle 
contraction.  
EDHF is an endothelial mediator that complements the vasodilator effects of NO and 
prostacyclin. A number of candidiates have been proposed to be EDHFs, including 
prostanoids, potassium ions, and C-type natriuretic peptide. Hyperpolarisation of the 
vascular smooth muscle decreases calcium influx and this leads to relaxation. The 
vasodilator effect of EDHF increases as the blood vessel size decreases such that 
their effect is thought to predominate in resistance vessels whereas NO is the 
principal vasodilator in conduit vessels(69). However, it is postulated that the EDHF-
mediated response might become more prominent when NO production is 
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compromised since mesenteric arteries for eNOS knockout mice showed an 
upregulation of EDHF (70).  
 
The endothelins are peptides that possess potent vasoconstrictor properties.  
Endothelial cells in humans produce endothelin-1(ET-1) and increased circulating 
levels of these have been correlated with the development of atherosclerosis and 
coronary endothelial dysfunction (71-73).  ET-1 acts via two major receptors; 
endothelin – A (ETA) which is present on vascular smooth muscle cells and 
endothelin – B (ETB) which is located on both vascular smooth muscle and 
endothelial cells. ETB receptors which are expressed on the endothelial cells mediate 
the release of NO and promote pulmonary clearance and endothelial reuptake of 
ET-1. This has been the justification for investigating the potential role of selective 
ETA   antagonists in the treatment of coronary artery endothelial dysfunction and 
hypertension (74-76).  
 
1.5.3   IR induced endothelial dysfunction 
Vascular endothelial cells are particularly susceptible to the effects of IR injury. Ku et 
al demonstrated that coronary artery endothelial dysfunction occurred after 90 
minutes of ischaemia and 1-2 hours of reperfusion in the canine heart (77). IR-
induced endothelial dysfunction was seen within the first few minutes of reperfusion 
whereas with ischaemia alone, significant impairment in endothelial response to 
vasodilators is only detected after 2 hours. 
Endothelial cells produce NO (via NOS) and superoxide (from a number of sources 
including NADPH oxidase). Under normal conditions, the rate of production of NO 
exceeds that of superoxide production. This allows for NO a) to effectively scavenge 
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the low intracellular levels of superoxide; b) to modulate arteriolar tone via the 
guanylate cyclase activation in smooth muscle; c) to inhibit platelet aggregation and 
thrombus formation and d) to minimise the adhesive interactions between leucocytes 
and the endothelial cell surface (20). After IR injury, this balance is reversed such 
that accumulation of superoxide occurs and NO production is impaired. NO 
synthesis depends on the availability of molecular oxygen, which is reduced during 
ischaemia. Superoxide production increases as a result of the mechanisms 
described in section 1.4.3.  The relatively low levels of NO react with the abundant 
supply of superoxide further reducing NO levels. The net effect is a reduction of 
endothelium-dependent vasodilatation and the production of other reactive oxygen 
species such as H2O2 and HOCl, which further impair endothelial function (20). In 
addition to impairment of endothelial function, reactive oxygen species promote 
inflammation and apoptosis which contribute to the process of cellular damage 
during IR.  
1.5.4 The vascular “no-reflow” phenomenon 
Another vascular manifestation of IR injury is the “no-reflow” phenomenon. This has 
been defined as incomplete and non-uniform reperfusion at the microvascular level 
despite adequate re-opening of the proximal artery after a period of transient 
ischaemia (78).  The importance of this phenomenon lies in the fact that it correlates 
with infarct size and provides useful prognostic information (79). Reperfusion is 
thought to cause microthromboemboli and particles of plaque to be showered 
downstream after plaque rupture, leading to obstruction of small arteries and 
arterioles (79). The major determinants of the degree of no-reflow are the duration of 
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occlusion, infarct size and length of reperfusion and no-reflow tends to persist over a 
period of at least 4 weeks (78).  
 
1.6 Protection against IR injury  
Over the last two decades, interventions that are protective against IR injury have 
emerged. Various models of IR injury (cell cultures, isolated perfused hearts and 
animal models in vivo) have been used to investigate strategies to reduce cellular 
and tissue damage. Some of these interventions have been translated to clinical 
studies in patients and could potentially lead to a significant reduction of reperfusion 
injury in the clinical setting. There are 4 types of intervention that are considered in 
this thesis; ischaemic preconditioning, ischaemic postconditioning, remote 
conditioning and administration of oral inorganic nitrate, each of which is discussed 
in turn below. 
 
1.7   Ischaemic preconditioning  
This was first described in 1986 when Murry et al demonstrated in an anaesthetized 
dog, that 5 minute periods of circumflex artery occlusion alternating with 5 minute 
periods of reperfusion prior to a 40 minute total occlusion of the same artery, 
reduced myocardial infarct size (80) [Figure 1.5]. The protective effects of 
preconditioning (IPC) have since been reproduced in animal and human models. 
The IPC stimulus is applied prior to the onset of index ischaemia and causes two 
phases of protection; a “classic” or “early” or “first window of protection (FWOP)” 
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phase and the “delayed” or “late” or “second window of protection (SWOP)” phase. 
Classic IPC, as described by Murry and colleagues, in which protection by IPC was 
lost when the interval between the IPC stimulus and the infarct protocol was 
extended beyond 60 minutes. Delayed IPC was based on a discovery that even 
though initial protection by IPC was lost after 60 minutes, protection re-emerged at 
24 hours, lasting for up to 72 hours (81-83).  
 
Figure 1.5: Original description of ischaemic preconditioning canine model of myocardial ischaemia 
reperfusion injury showing reduction in infarct size with episodes of circumflex artery occlusion-reperfusion prior 
to the injurious ischaemia in dogs (80). 
 
 
1.7.1   Mechanisms of ischaemic preconditioning  
IPC promotes the accumulation of protective ligands (triggers) which activate a 
number of mediators and through a complex process of cell signalling protection 
against IR injury is conferred by end effectors. In delayed IPC there is prominence of 
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gene transcription and synthesis of new proteins rather than activation of existing 
proteins. This enables a sustained period of protection after the FWOP. However the 
mechanisms of early and delayed IPC remain similar [Figure 1.6a & b]. 
 
1.7.1.1     Triggers of ischaemic preconditioning 
The IPC stimulus promotes the release and accumulation of triggers which initiate 
the process of ischaemic protection. Adenosine (84, 85), bradykinin (86, 87), opioids 
(88-90), NO (91) and acetylcholine (92, 93) have all been identified as triggers and 
act via cell surface G-coupled receptors. Evidence for involvement of these ligands 
in IPC stems from studies that show that the protective effects of IPC are abolished 
in receptor knockout animals or with pharmacological blockade of their respective 
receptors. The receptors are proposed to act in parallel such that pharmacological 
antagonism of an individual receptor raises the ischaemic threshold required to 
trigger protection by IPC (94). Other autacoids implicated as triggers of IPC include 
free radicals (95, 96), norepinephrine (97) and CGRP (98). 
 
1.7.1.2    Mediators of ischaemic preconditioning 
The triggers of IPC activate second messengers including protein kinase C epsilon 
(PKCε), tyrosine kinases, phophatidylinositol 3-kinase (PI3K), Akt, mitogen-activated 
protein kinase (MAPK), extracelluar receptor kinase (ERK), JAK/STAT and nuclear 
factor κB (94). In addition, some downstream proapoptotic proteins are inactivated. 
These include glycogen synthase-3β (GSK-3β) and the Bcl-2 proteins – Bad and 
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Bax (99-101). eNOS activation leads to generation of NO and this activates protein 
kinase G via elevation of intracellular cGMP. Some downstream consequences of 
PKCε include KATP channel opening which further enhances PKCε production and 
generates ROS which is thought to be an essential part of the signalling cascade 
(Figure 1.6a).  
The transcriptional regulator, nuclear factor kappa B (NF-κB) plays a prominent role 
in the modulation of several genes during delayed IPC. This was evident in studies 
which showed that delayed IPC induced NF-κB activation and the NF-κB inhibitor 
DDTC blocked the protective effect of delayed IPC in a rabbit model of IR Injury 
(102). This  group also demonstrated that delayed IPC-induced activation of NF-κB 
and ischaemic protection was blocked by pre-treatment with the NOS inhibitor NG-
nitro-L-arginine (L-NA), the ROS scavenger N-2-mercaptopropionyl glycine, the PKC 
inhibitor chelerythrine and the tyrosine kinase inhibitor lavendustin A (102). The 
results highlighted the importance of activation of these pathways during delayed 
IPC and the possible role of NF-κB as the common distal pathway of delayed IPC. 
NO has often been considered to act as both a trigger and a mediator during 
delayed IPC.  eNOS releases NO following the IPC stimulus and iNOS mediates the 
formation of NO which confers protection 24-72 hours later. This is indicated by a 
biphasic response in measured NOS activity, though there appears to be a degree 
of overlap (103). The loss of the delayed IPC-induced ischaemic protection with a 
pharmacological inhibition of NOS or in iNOS knockout mice implicates a role for NO 
and specifically iNOS in delayed IPC (104, 105).   
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1.7.1.3   Effectors of ischaemic preconditioning 
KATP channels are proteins that play a key role as effectors of the IPC stimulus.  KATP 
channels consist of inward rectifier potassium channels (KIR) and sulfonylurea 
receptor (SUR) subunits which form functional units (106, 107). Isoforms of KIR 
(KIR6.1 and KIR6.2) and SUR (1, 2A, 2B) result in heterogeneous populations of KATP 
channels, with differing tissue specificity (108, 109).  KATP channels are present the 
plasma membrane (sarcolemmal KATP channels) and mitochondria (mitochondrial 
KATP channels).  Both populations are thought to have a similar structure and are 
implicated in IPC (110).  
Evidence of involvement of KATP channels arises from studies in which the 
pharmacological antagonists (glibenclamide – nonselective; HMR1098 – selective 
for sarcolemmal KATP channels; 5-hydroxydecanoate – selective for mitochondrial 
KATP channels) abolished the protection by IPC and pharmacological KATP channels 
openers such as diazoxide and nicorandil mimicked protection by IPC (94). In 
addition, the loss of protective effect of IPC in KATP channel knockout mice models of 
IR injury has implicated their role in the mechanism of IPC (111). Evidence suggests 
that the mitochondrial KATP channels play a more prominent role in IPC, activation of 
which prevents opening of the mPTP, thereby reducing IR injury (see section 1.4.2) 
(112, 113). Suggested mechanisms by which KATP channel activation inhibits the 
mPTP include reduction in mitochondrial calcium load (promoting efflux or reducing 
entry), improvement in mitochondrial energy production by enhancing oxidative 
phosphorylation and reduction of ROS levels (113). Possible end effectors that play 
a role specific to delayed IPC includes heat shock proteins (HSP), iNOS, COX and 
antioxidant enzymes (94, 114). 
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Figure 1.6:  Major mechanisms of ischaemic preconditioning (IPC). (a) Early IPC promotes the 
accumulation of protective ligands (green panels) which activates a complex cascade of intracellular events. 
Interestingly the opening of the mKATP channels by PKC activation generates ROS which further activation of 
PKC. Inhibition of processes which facilitate mPTP opening (red panels) forms an essential part of the 
mechanism of early IPC. (b)Similarly, the triggers of late IPC activate a signal transduction process that entails 
activation of kinases and transcription factors and gene transcription. These processes facilitate the formation of 
new proteins which serve as effectors (Adapted from Stein et al 2004). 
 
1.7.2   Clinical application of ischaemic preconditioning 
Since the description of IPC, it has consistently produced significant reduction in IR 
injury in several experimental models. Yellon and colleagues demonstrated the 
reduction of myocardial injury in patients undergoing coronary artery bypass surgery 
using IPC which comprised cross clamping of the aorta (115). Following this, a 
number of studies demonstrating cardioprotection with IPC protocols  have been 
performed in patients undergoing elective procedures such as  aortic and mitral 
valve replacements and coronary artery by-pass surgery(116, 117). Furthermore, 
studies have shown that pre-infarct angina might serve as an IPC stimulus and 
b. 
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confer cardioprotection in patients who present with acute myocardial infarction 
(118-120). One major concern has been the safety of the IPC stimulus which often 
involves intermittent clamping and unclamping of the aorta or brief coronary artery 
occlusion and reperfusion in minimally invasive coronary artery by-pass surgery. In 
addition, some organs, such as the brain, are at a risk of IR injury but not accessible. 
This created the need to develop preconditioning mimetic drugs which could be 
administered prior to elective procedures or prophylactically in high risk patients. 
Based on the knowledge of the molecular mechanisms of IPC, mimetics such as 
adenosine, nicorandil and nitroglycerin have been tested in humans but have 
produced mixed results (21,121). Another hindrance to the clinical development of 
IPC is that it is not applicable during unplanned ischaemic syndromes.  
In summary, IPC is an established method of ischaemic protection but two issues 
limit its clinical application. Firstly, there are risks associated with brief periods of 
ischaemia to vital organs. Secondly, most cardiovascular events are unpredictable, 
making it impossible to schedule any such prior preconditioning events. It has 
therefore been necessary to explore other strategies which might be more clinically 
applicable.     
 
1.8   Ischaemic postconditioning  
Another form of ischaemic protection, discovered more recently, is known as 
ischaemic postconditioning (PostC).  Zhao and colleagues showed in a canine 
model, that after a 45 minute episode of sustained myocardial ischaemia, the 
interruption of myocardial reperfusion with three 30 second cycles of alternating 
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reperfusion/ischaemia reduced the myocardial infarct size by almost 50% (122). 
Furthermore, this schedule of interrupted reperfusion (PostC) also prevented 
coronary artery endothelial dysfunction, and neutrophil accumulation in the area at 
risk. Results of this study not only identified a novel method of ischaemic protection 
but also demonstrated that its protective effect was comparable to IPC. 
The application of the PostC stimulus early in reperfusion is crucial. This is evident in 
the loss of protection with as little as a one minute delay in application PostC 
(123,124). Different schedules of PostC have been demonstrated to be protective 
and include (3-6) cycles of brief (10-30 seconds) alternating ischaemia/reperfusion 
(125,126). 
PostC clearly influences specifically the reperfusion phase of IR injury, yet in general 
it has a similar degree of ischaemic protection as IPC (122, 127,128). This suggests 
that much of the reversible tissue injury following arterial occlusion happens early in 
the reperfusion phase. An additive cardioprotective effect when both stimuli are 
applied has been observed in the rat, but results have not been consistent in rats 
and across species (127-131). One interpretation of this is that in most species there 
is mechanistic overlap between IPC and PostC. The additive effect seen in the some 
rat models is consistent with a smaller degree of protection by PostC or a larger 
component of ischaemic injury in this species.  
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1.8.1 Mechanisms of postconditioning  
The mechanisms of PostC resemble that of IPC and can be considered in similar 
terms: triggers, mediators, effectors [Figure 1.7]. 
 
1.8.1.1 Triggers 
PostC promotes the accumulation or delays the washout of cardioprotective ligands 
which activate G-protein coupled receptors (132), many of which have been 
implicated in IPC. Adenosine is involved as non-selective pharmacological 
antagonism (8-ρ-sulfophenyl theophylline) of adenosine receptors during reperfusion 
abolished the protective effect of PostC (133, 134). Studies with selective adenosine 
receptor ligands have suggested a role for A2 receptor subtypes (A2A in mouse and 
A2B in rabbits) in PostC (133, 135). Bradykinin B2 receptors have also been 
implicated in PostC, because  5 cycles of 10 seconds intermittent bradykinin infusion 
triggered PostC-like protection and the non-peptidic bradykinin B2 receptor 
antagonist - WIN64338 blocked PostC (136). Endogenous opioids appear to have a 
role because the protective effects of PostC are blocked by the non-selective opioid 
receptor antagonist naloxone and the selective [delta]-opioid receptor antagonist 
naltrindone (137,138). Erythropoietin (EPO) receptor expression in hypoxic tissues is 
increased and higher endogenous EPO levels have been associated with smaller 
infarct sizes in patients undergoing PCI for acute myocardial infarction (139). Indeed 
administration of EPO at reperfusion also reduces infarct size in several animal 
models but this protective effect is yet to be reproduced in humans (140-142). 
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1.8.1.2 Mediators 
The endogenous protective ligands described above are thought to cause the 
activation of intracellular signalling molecules and prosurvival kinases, and similar to 
IPC.  
Prosurvival kinases (reperfusion injury salvage kinases, RISK) activated during IPC 
have been implicated in PostC (143, 144). They include PI3/ Akt, ERK 1/2, JNK, 
Protein kinase C, Protein kinase G and p70S6K. Using a rat isolated heart model, 
PI3K/Akt activation has been identified as a mediator of PostC because the 
administration of PI3K inhibitors (LY294002 or wortmannin) in the first 15 minutes of 
reperfusion inhibited PostC induced protection (131). Similarly, PD98059, a 
MAPK/ERK inhibitor aborted the protection afforded by PostC in rabbit myocardium, 
thus identifying a role for MAPK/ERK in PostC (145). PostC has also been found to 
be dependent on protein kinase C (PKC) signalling in that the infarct-sparing effect 
of PostC was abrogated by the non-selective PKC inhibitor, chelerythrine and 
PKCepsilon inhibitor, KIE1-1 (146). Administration of the PKCdelta inhibitor, rottlerin 
seemed to mimic the protective effect of PostC. These data suggest that there is an 
increase in PKCepsilon activity and a reduction in PKCdelta activity in PostC as is 
the case for IPC. Acidosis might have a direct co-stimulating effect on these kinases; 
phosphorylation of Akt and ERK induced by postconditioning was blunted by the co-
treatment with sodium bicarbonate (147).  
Several interventions have been shown, experimentally, to elicit cardioprotection 
when administered at the time of reperfusion through activation of the RISK pathway 
and include insulin, IGF-1, erythropoetin, G-CSF, leptin, atorvastatin, pioglitazone, 
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atrial natriuretic peptides (ANP), Rho kinase inhibitors (Fasudil) and oestrogen (144). 
This highlights the importance of the RISK pathway in cardioprotection and creates 
the potential for use of some of these agents clinically. In addition to the up-
regulation of antiapoptotic kinases, PostC causes downstream inhibition of 
proapoptotic proteins such as GSK-3β and members of the Bcl-2 protein family 
(Bad, Bax) (148, 149).  
The demonstration of increased eNOS-ser1177 phosphorylation after PostC and the 
loss of protection by PostC with a selective soluble guanylyl cyclase (sGC) inhibitor 
(1H-[1, 2, 4]oxadiazolo[4,3-α] quinoxalin-1-one, ODQ) is evidence that 
GC/NO/cGMP pathway is involved in PostC  (131, 134). In addition, in a rabbit heart 
model of IR injury, infusion of the NOS inhibitor, N-nitro-L-arginine methyl ester (L-
NAME) before the onset of reperfusion caused a loss of protection by PostC (145). 
Subsequently Penna and colleagues have demonstrated, in rat isolated hearts, that 
NOS and sGC play different roles in PostC. Their study revealed that the protection 
afforded by PostC was only blunted by the NOS inhibitor, L-NAME but fully 
abolished by the sGC inhibitor, ODQ suggesting an additional route of activation of 
sGC by PostC which is NOS-independent (150).  
Signaling, via NO, leads to accumulation of cGMP which causes activation of PKG. 
During rapid re-oxygenation (simulated IR injury) of adult rat cardiomyocytes, the 
presence of the PKG activator – 8-pCPT-cGMP or the cGMP analogue – 8-bromo-
cGMP, increased  sarcoplasmic Ca2+ - ATPase (SERCA) activity which reduced the 
peak intracellular calcium concentration and cardiomyocyte hypercontracture (151).  
These effects were abrogated by KT5283, a specific inhibitor of PKG. Some 
investigators have proposed that PKG is the terminal cytosolic component of the 
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trigger pathway and exerts its protective effect on the inner mitochondrial membrane 
via a signaling mechanism that involves KATP channels and PKC (152). 
PostC is also thought to be associated with the reduction of ROS generation which 
contributes to reperfusion injury (123, 153).  In contrast, administration of the ROS 
scavenger N-acetylcysteine (NAC) before or during PostC abolished protection 
(154). This was not the case when NAC was administered after PostC. This 
suggests that ROS generation has complex effects, and may play a role in signaling 
cardioprotection. 
 
1.8.1.3 Effectors 
As with IPC, KATP channels have been implicated in the mechanism of PostC. In a 
rabbit model of myocardial IR injury, the non-selective KATP channel blocker, 
glibenclamide and the mKATP channel blocker 5-Hydroxydecanoate (5-HD) 
administered at the onset of reperfusion, abrogated the protective effect of PostC 
(145). Recently, Myktenko and colleagues demonstrated that the infarct sparing 
effect of PostC, in a canine model of IR injury, was abolished by the administration 
of 5-HD, a mKATP channel blocker. However, in the presence of HMR1098 - a 
sarcKATP channel blocker, the protective effect of PostC was not affected (155). In 
the same study, PostC up-regulated expression of mKATP channel Kir6.1 protein. 
These data suggest a specific role for mKATP channels in PostC. Activation of mKATP 
channels is thought to mediate inhibition of mPTP opening as described above. 
A role for the mPTP in PostC was first reported by Argaud and colleagues who 
demonstrated that the specific inhibitor of the mPTP, NIM811, administered around 
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the onset of reperfusion, limited infarct size in rabbit hearts to a degree comparable 
to IPC and PostC (156). In addition, they showed that mitochondria isolated from 
postconditioned myocardium displayed an increased resistance to Ca2+ loading and 
this was similar to the hearts that underwent preconditioning or treatment with 
NIM811.  
Cardioprotection by inhibition of the mPTP around the time of reperfusion has been 
explored in an acute angioplasty model in humans (157). Intravenous administration 
of a bolus dose of the mPTP inhibitor, ciclosporin, immediately before percutaneous 
coronary intervention (PCI) caused a significant reduction of creatine kinase 
compared with the control group.  
The exact mechanism by which PostC inhibits opening of the mPTP is yet unknown. 
Recently, it has been suggested that PostC is critically dependent on both 
maintenance of myocardial acidosis during the initial 2 minutes of reperfusion and 
the simultaneous supply of oxygen (158). Using an rabbit isolated heart model, it 
was  demonstrated that protection by PostC was lost when the heart was reperfused 
with an alkaline perfusate, even when the cardioprotective signalling cascade was 
triggered by activators of PKC (phobol 12-myristate 13-acetate [PMA])  or GSK-3β 
(SB216763), the latter being a downstream molecule. However the protection by 
PostC was restored with the addition of ciclosporin suggesting that ciclosporin is a 
more potent inhibitor of mPTP.  It was also observed that in the presence of a 
hypoxic acidic perfusate, PostC was ineffective. It was postulated that an 
oxygenated acidic environment was necessary to block the mPTP opening long 
enough so that signalling could be triggered leading to endogenous attenuation of 
mPTP opening even after the correction of myocardial pH (158). Other mechanisms 
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by which PostC inhibits mPTP opening have been proposed and can be divided into 
indirect (intracellular calcium regulation, ATP preservation, oxidative stress 
correction) and direct (the phosphorylation and translocation of various protein 
kinases such as Akt, ERK1/2, GSK-3β, PKG, and PKC-ε) (159).  
1.8.2   Clinical application of ischaemic postconditioning 
Ischaemic protection by PostC is an attractive protective strategy especially 
considering its applicability and effectiveness in the acute ischaemic setting. Since 
first demonstration in humans, PostC has been successfully applied to patients in 
the setting of acute coronary angioplasty and has been associated with reduction of 
infarct size, improved endothelial function and improved resolution of ST-segments 
(160-162). PostC has also been protective during elective valve replacement, when 
the adult myocardium undergoes cold blood cardioplegic arrest (163). In addition, 
PostC has been protective during surgical correction of congenital heart disease in 
children (164).     
The long term clinical effect of PostC in patients is yet to be established. In a recent 
acute coronary angioplasty study, not only did the postconditioned group of patients 
exhibit a reduced infarct size but also, at one year, a 7% increase in left ventricular 
ejection fraction compared with controls was observed (165). The limitation of this 
study is the small number of patients, and much larger studies with long term follow-
up will be needed to define its clinical usefulness. 
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Figure 1.7: Mechanisms of postconditioning. PostC is thought to promote the accumulation or delay the 
wash out of protective ligands (adenosine, bradykinin, opioids etc.) which activate a complex cascade of 
intracellular events. These processes are protective (green panels) in themselves or lead to inhibition of 
deleterious products of IR that exacerbate injury (red panels). Ultimately, these intracellular events seem to 
cause protection by preventing opening of the mPTP.  
 
1.9   Remote ischaemic conditioning 
IPC also has protective effects at sites remote from those exposed to the ischaemic 
preconditioning stimulus, and this facet of IPC has been termed remote ischaemic 
preconditioning (RIPC). This was first reported in anaesthetised dogs when regional 
ischaemic 'preconditioning' protected remote virgin myocardium from subsequent 
sustained coronary occlusion (166). This study hinted that IPC had systemic 
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protective effects that were confirmed when it was shown that preconditioning the 
kidney (167, 178), intestine (168, 178) or limb (169) provided protection against IR 
injury in the heart and other tissues. This form of protection entailed application of 
the remote stimulus in advance of the ischaemic insult and is termed remote 
ischaemic preconditioning (RIPC).  More recently, remote postconditioning 
(RPostC), a variant of RIPC, has also been described. In RPostC, the conditioning 
stimulus is applied during the ischaemic insult making it a more convenient remote 
stimulus in the acute ischaemic setting (170, 171).  In this thesis I will use the term 
remote ischaemic conditioning as a blanket term for the two types of remote 
ischaemic protection.   
RIPC shares similar signaling mechanisms to those of IPC and experimental models 
have implicated similar triggers, mediators and effectors (167, 170-173). This has 
been discussed in section 1.6.1 of this thesis. 
 
1.9.1   Mechanisms of transfer of remote protection 
One of the most intriguing aspects of remote protection is the mechanism of 
systemic spread of protection from the site undergoing conditioning. Humoral and 
neurogenic pathways have been proposed, with the potential for a degree of overlap 
between them [Figure 1.8].   
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1.9.1.1   Humoral mechanism 
Coronary effluent from a preconditioned heart induces myocardial protection in non-
preconditioned hearts, an effect that was blocked by administration of the non-
specific opioid receptor blocker, naloxone to the recipient (174). This implicated the 
opioid receptor pathway in the spread of remote protection and highlighted the 
importance of circulating opioids. Furthermore it was shown that in the rat isolated 
heart, infarct size was reduced by plasma and dialysate of plasma (obtained using a 
15 kDa cut-off dialysis membrane) from donor rabbits subjected to RIPC (174). In 
addition, the dialysate of plasma from rabbits and humans subjected to RIPC, 
reduced necrosis in an isolated fresh cardiomyocyte model of simulated ischaemia 
and reperfusion. Interestingly, these protective effects were abrogated by naloxone, 
suggesting that cardioprotection by RIPC occurred across species, required opioid 
receptor activation but did not require an intact nervous system. More recently 
however, the same group has demonstrated that the intra-arterial injection of 
adenosine into the femoral artery or limb RIPC released dialysable cardioprotective 
factor(s) in a manner that was dependent on an intact femoral nerve (175). With 
prior femoral nerve transection in the donor rabbit, the dialysate was no longer 
protective in the Langendorff perfused rabbit heart. This suggests a plausible 
interaction between a neurogenic and humoral mode of transfer. Opiates are not the 
only implicated humoral factor, with evidence for prostaglandins (176) and 
unidentified hydrophobic compounds (177). 
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1.9.1.2   Neurogenic mechanism 
Neurogenic mechanisms have also been explored using autonomic ganglionic 
blockade. In a rat myocardial infarction model (60 minutes coronary artery occlusion 
with 3 hours of reperfusion), Gho et al showed that the ganglion blocker 
hexamethonium abolished protection by RIPC achieved by 15 minutes of mesenteric 
artery occlusion-reperfusion (MAO) but had no effect on local myocardial IPC 
achieved by 15 minutes of coronary artery occlusion-reperfusion(178). 
Cardioprotection was absent when MAO was sustained throughout the study, 
indicating that reperfusion in the small intestine was essential to activate the 
neurogenic pathway. In a similar study, using a rabbit model of myocardial IR injury, 
an intramesenteric artery infusion of bradykinin (BK) at a dose that stimulates 
sensory nerves without systemic effects mimicked these protective effects of RIPC. 
Protection was abolished by both the bradykinin 2 (BK2) receptor antagonist, HOE- 
140 and the ganglion blocker, hexamethonium (179).  Pre-treatment with HOE-140 
did not have an effect on infarct size of non-preconditioned rabbits. The researchers 
propose that the BK2 receptor activates local afferent nerves and lead to protection 
via the autonomic nervous system. These data corroborate a previous study in 
which HOE-140 abolished ischaemic protection by IPC in an intact rabbit heart but 
failed to block protection by IPC in an isolated rabbit heart (180). This suggested that 
protection by bradykinin was dependent on an intact autonomic nervous system. An 
increase in the release of the neurotransmitter glutamate and an increased 
expression of bradykinin receptors in cultured rat dorsal route ganglia sensory 
neurons, in response to increasing bradykinin concentration has been demonstrated 
in in vitro studies (181, 182).   
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In an in vivo rabbit model of myocardial infarction, RIPC by renal artery occlusion 
reduced infarct size by 46% (183). This protection was abolished by intravenous 
pretreatment with the nonselective adenosine receptor antagonist; 8-SPT. During 
renal RIPC, the renal afferent nerve discharge increased but this was attenuated by 
administration of intravenous 8-SPT. Furthermore, renal nerve resection abolished 
the protective effects of RIPC. These data suggest that the renal sympathetic nerve 
responds to adenosine receptor activation and triggers spread of protection beyond 
the kidney.  
There is also experimental evidence that calcitonin gene-related peptide (CGRP), a 
neurotransmitter in capsaicin sensitive sensory nerves (CSSN), is implicated in the 
mediation of the delayed phase of remote organ protection. In a rabbit model of 
myocardial infarction RIPC induced by transient ischaemia of the small intestine, 
caused a reduction in infarct size and creatine kinase with an increase in plasma 
levels of CGRP (184). In this study, the protective effect of intestinal RIPC was 
abrogated by pre-treatment with capsaicin administered systemically, which 
selectively deletes neurotransmitters in the CSSN. Capsaicin also prevented an 
increase in the plasma level of CGRP. In another study using a pig model of 
myocardial ischaemia reperfusion injury, administration of the CGRP antagonist – 
CGRP (8-37) locally or systemically by intravenous infusion, did not influence infarct 
size. (185). Other studies have shown that the release of CGRP occurs in response 
to transient ischaemia, hyperthermia or endogenous ligands such as bradykinin 
(186). These data support the thesis that release of endogenous ligands in the 
remote organ activates afferent nerves which mediate the transfer of protective 
effects of RIPC. 
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The role of the nervous system in remote conditioning has also been demonstrated 
in humans using an in vivo model of vascular IR injury. The autonomic ganglion 
blocker, trimetaphan, had no effect on endothelial IR injury but abolished the effect 
of early and late RIPC to prevent such injury (187).  
 
1.9.2   Clinical application of remote conditioning 
RIPC obviates the need for complex and invasive IPC protocols because the 
protective stimulus can be applied non-invasively to a limb), without risking the blood 
supply to a vital organ. The first study to associate limb ischaemia with remote 
protection used a composite of electrical stimulation of skeletal muscle and arterial 
obstruction, to reduce myocardial infarct size in rabbits (188). This study was 
followed by the demonstration in humans, using an in vivo model of endothelial IR 
injury, that remote transient limb ischaemia was protective (169). The protective 
effect of RIPC by transient limb ischaemia has since been reproduced in a number 
of studies in patients (189). However, in the acute ischaemic setting RIPC is not 
applicable. RPostC which entails the application of the RIPC stimulus after the onset 
of injurious ischaemia has been described and in a clinical study of patients with ST-
elevation myocardial infarction, who received RPostC in the ambulance prior to PCI, 
there was a significant myocardial salvage (190).  Further studies to harness the full 
potential of this form of protection are on-going. 
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Figure 1.8: Mechanisms of transfer of protection by remote conditioning.  Protection by RIPC and 
RPostC is thought to be transferred to the site of injurious ischaemia via a neurogenic pathway or circulating 
substances (humoral pathway). An interaction between the two pathways is plausible but their relative 
contribution to overall protection merits further investigation.  
 
 
1.10 Ischaemic protection by inorganic nitrates and nitrites 
As stated above (section 1.5.2) reduction in the NO bioavailability is a key event 
during IR injury resulting mainly from disruption to normal oxygen dependent 
endothelial production of NO. In addition, NO-cGMP signalling has been implicated 
in the mechanism of ischaemic preconditioning and postconditioning. NO donors 
reduce IR injury in a variety of experimental models, though clinical trials of NO 
donors to reduce IR injury have been negative (222). Recently, interest in a parallel 
pathway for NO generation that is activated at times of oxygen depletion, has led to 
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a reappraisal of the role of exogenous NO-supplementation as a potential treatment 
for IR injury.  This pathway is the nitrate-nitrite-NO pathway [Figure 1.9] and is 
described in the next section. 
 
1.10.1 NO generation – the alternative pathway  
Within the cardiovascular system NO is generated largely via the activity of the 
eNOS enzyme (191-193). By this mechanism, NO is made available for 
physiological functions which may contribute to ischaemic protection as described in 
sections 1.7.1.2 and 1.8.1.2. Under the influence of the oxyhaemoglobin, a 
significant proportion of the circulating NO is rapidly oxidised to NO2- (nitrite), which 
is itself oxidised to the more stable NO3- (nitrate) (194, 195). Previously, nitrite and 
nitrate were considered to be inert end products of NO metabolism but current 
research findings are changing this view. The hypoxic environment promotes the 
reduction of nitrites and nitrates to produce NO. This alternative (NOS-independent) 
pathway for NO generation predominates over the NOS-dependent pathway under 
conditions of hypoxia and acidosis such as occurs with IR injury (196). The 
implication is that endogenous nitrite and nitrate stores act as a backup source of 
NO which may be beneficial during IR injury. 
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Figure 1.9: The nitrate-nitrite-NO pathway. An alternative pathway for NO generation which is activated 
hypoxic and acidotic conditions when the NOS-dependent pathway is dysfunctional. 
 
1.10.2   Enterosalivary circulation of nitrates in humans 
Ingested nitrates are rapidly absorbed in the small intestine and distributed in the 
blood to other parts of the body, and whilst up to 75% is eventually excreted in the 
urine, 25% is taken up by the salivary gland [Figure 1.10] (197). This nitrate is then 
secreted into the saliva and reduced to nitrite by bacterial nitrate reductases on the 
dorsum of the tongue [Figure 1.10] (198).  The nitrite-rich saliva is swallowed and 
enters the stomach where under the acidic conditions, some of this nitrite is 
converted by simple chemical acidification to NO (198, 199). However, it is thought 
that at least some of this nitrite enters the circulation where it may then be converted 
to NO by nitrite reductases (200, 201).  The importance of the enterosalivary 
production of nitrite has been highlighted in studies that show that a disruption of 
enterosalivary pathway, by preventing swallowing of nitrite-rich saliva or use of anti 
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bacterial mouthwash, results in a lack of a corresponding increase in circulating 
nitrite levels after ingestion of an oral inorganic nitrate load (202, 203).  
Reduction of nitrite to NO in the circulation has been shown to be facilitated by a 
number of different candidates including deoxyhaemoglobin, xanthine 
oxidoreductase and mitochondrial enzymes, activities of which are enhanced in 
ischaemic environments, i.e. nitrite reduction to NO increases with decreasing pH 
and pO2 (198). In addition, reduction of nitrite to NO via eNOS has been described 
(204). In particular it has been suggested that eNOS might act as a nitrite reductase 
when conventional eNOS activity (ie. L-arginine conversion to NO) is impaired such 
as in low O2 conditions (205, 206). This enterosalivary circuit and intravascular 
processing enables oral inorganic nitrates and nitrites to serve as an intravascular 
reservoir for NO under hypoxic and acidotic conditions.  
Systemic nitrite is derived from oxidation of NO in the plasma, reduction of salivary 
inorganic nitrate and from dietary sources such as meat, vegetables and drinking 
water (207).  Accordingly under fasting conditions, the majority of nitrite is thought to 
be from oxidation of NOS derived NO. The reduction of circulating nitrite to NO 
under hypoxic and acidotic conditions that occurs during ischaemia, might have 
biological effects to limit tissue injury.   
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Figure 1.10: Enterosalivary circulation of nitrate in humans. A proportion of the absorbed nitrate (purple 
circle) is taken up by the salivary gland, secreted into the saliva and reduced to nitrite (orange circle) by 
reductases present on the dorsum of the tongue. This is swallowed and in the acidic environment of the stomach 
is further reduced to NO (green circle). This enterosalivary circulation of nitrate is thought to provide an 
alternative source of NO in conditions of hypoxia and acidosis such as during IR injury. 
 
1.10.3 Nitrites and protection against IR injury 
Johnson and colleagues discovered that administration of acidified sodium nitrite, 
during ischaemia, resulted in a significant reduction of myocardial injury in cats 
(208). This was indicated by lower creatine kinase (CK) levels and a reduced 
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necrotic area (expressed as percentage of myocardial area at risk) on nitroblue 
tetrazolium staining compared to controls. Using the isolated rat Langendorff heart 
model, Webb et al demonstrated that provision of nitrite during the ischaemic period 
or at reperfusion significantly reduced myocardial infarct size; an effect associated 
with comparable improvements in recovery of LV function (209). In this study, the 
importance of reduction of nitrite to NO was highlighted by the demonstration that 
protection was lost in the presence of the NO• scavenger 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide (carboxy-PTIO). This apparent loss of 
nitrite-induced ischaemic protection with carboxy-PTIO has since been 
demonstrated in a number of other animal studies (210-212). Using animal models 
of IR injury, it is now evident that nitrite is protective in the heart (209, 213-217), liver 
(211, 213, 215), kidney (212) and brain (218, 219). The role of nitrite-dependent NO 
in ischaemic protection is also highlighted in a study by Bryan et al in which dietary 
nitrite restored NO and nitrite bioavailability in eNOS knockout mice to steady state 
levels which were sufficient to protect against myocardial IR injury (214). This study 
provides evidence that dietary nitrites can act as alternative sources of NO in 
conditions associated with a dysfunctional NOS pathway.  
The exact mechanism of the beneficial effects of nitrite-derived NO is debatable. 
Nitrite-dependent NO production during hypoxia is thought to regulate mitochondrial 
respiration by inhibiting respiratory chain complexes, thereby regulating the oxygen 
gradient and mediating cytoprotection during IR injury (213, 220). Nitrite-derived NO 
might also activate sGC and promote cGMP-dependent mechanisms of ischaemic 
protection. 
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1.10.4   Clinical application of nitrates and nitrites in ischaemic protection 
In clinical practice, organic nitrates, mainly in the form of nitroglycerin (GTN), have 
been used for the symptomatic treatment of coronary artery disease for over a 
century (221). GTN is thought to exert its biological effects via the release of NO. 
However, ISIS 4 showed that isosorbide mononitrate had no effect on mortality in 
acute myocardial infarction, and this has limited enthusiasm for further clinical study 
of the therapeutic effect of NO-supplementation (222). As for other failed 
interventions in clinical IR injury, it remains uncertain if the organic nitrate was 
administered at the optimal time-point.  
Another clinically relevant approach to NO delivery to tissues is administration in the 
inhaled form. Previously, the biological effects of inhaled NO (iNO) were thought to 
be limited to the pulmonary vasculature without any extrapulmonary bioactivity. Fox-
Robichaud and colleagues disproved this by demonstrating, in feline mesentery 
treated with the NOS inhibitor – L-NAME, that the local vasoconstriction and 
leukocyte recruitment was abolished by iNO (223). Subsequent studies using animal 
and human models of IR injury have shown that iNO may exert protective effects in 
the liver (224), heart (225, 226) lung (227) and lower limb (228). Large scale clinical 
trials and potential widespread clinical use of iNO in the clinical setting have been 
hindered by lack of convincing preliminary human data, complex dose titration and 
storage issues, possibility of rebound hypertension or hypoxia with acute use, the 
risk of developing methemoglobulinemia and the accumulation of toxic oxidants such 
as NO2 and peroxynitrite (229-231). Currently, iNO is licensed only for persistent 
pulmonary hypertension in neonates (230).  
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There is now compelling experimental evidence, from several studies, to support 
nitrite therapy in protection against IR injury in animals. The reduction in infarct size 
by a sodium nitrite infusion in the last 5 minutes of ischaemia during acute 
myocardial infarction in dogs sets the stage for the potential clinical use of nitrites as 
adjuvant cardioprotective therapy (232).  Inorganic nitrate and nitrite have potential 
to deliver NO specifically to ischaemic tissues, in a manner that might optimise the 
local therapeutic effect and minimise systemic effects.  
The inorganic nitrates and nitrites thus provide a substrate for the endogenous NO 
production in time of need, necessitating further assessment of their role in 
protection against IR. 
 
1.11   Translation of protective therapies into clinical use 
The ultimate aim of strategies to reduce IR injury lies in the translation of research 
findings into clinical use in order to derive the full benefit of improving outcomes in 
the management of cardiovascular ischaemia.  
Previous therapies aimed at reducing the lethal reperfusion injury in patients with 
myocardial infarction have not been successfully translated into clinical use. These 
include antioxidants, calcium overload and Na+-H+ exchange inhibitors, anti-
inflammatory agents, magnesium, therapeutic hypothermia, and glucose, insulin and 
potassium (21). Perhaps the pathogenesis of human IR injury is more complex than 
in the animal models that are used to validate drug targets. Some of the differences 
that have been highlighted include age and health of subjects, ischaemia/reperfusion 
times, timing of intervention and end points for cardioprotection (21). Future studies 
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should be aimed at using more clinically relevant animal models with robust study 
designs that will correlate with human studies. The utility of human mechanistic 
studies to bridge the gap between animal data and clinical trials in patients cannot 
be overemphasised. 
 
1.12 The human forearm model of IR injury 
The human forearm has served as a valid in vivo model to investigate the 
mechanisms of ischaemic protection in humans (53, 124, 169, 171, 187, 233). The 
ability to measure IR induced endothelial dysfunction in the human forearm has 
enabled the mechanistic assessment of different protective strategies. IPC, PostC 
and remote conditioning have all previously been shown to protect against 
endothelial IR injury in the human forearm.  
 
1.13   Aims of thesis 
Using the human forearm model of IR injury I sought to determine whether RIPC, 
RPostC and PostC protect against endothelial IR injury in conduit and resistance 
vessels.  
In chapter 3, I investigated the role of KATP channels and the mPTP in mechanism of 
PostC in humans. These targets can be manipulated using pharmacological tools. 
PostC has previously been shown to protect against endothelial IR injury in the 
brachial artery (124).  I assessed the effects of PostC on endothelial IR injury in the 
brachial artery and resistance vessels. Using this in vivo model of endothelial IR 
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injury, KATP channels have previously been implicated in IPC and RIPC (171, 233). I 
investigated whether the non selective KATP channel blocker, glibenclamide 
abrogates the protective effect of PostC and also determined the effects of the more 
pancreatic selective KATP channel blocker, glimepiride on PostC. This was to 
establish a role for KATP channels in PostC and investigate the effects of agents with 
different selectivity on PostC. Opening of the mPTP has been implicated as an 
effector mechanism in PostC (156, 159). I sought to determine if the administration 
of ciclosporin, a known inhibitor of the mPTP opening, administered around the 
onset of reperfusion protects against endothelial IR injury. This might be evidence 
that ciclosporin mimics PostC.  
In chapter 4, I investigated the role of the opioid receptor pathway in remote 
conditioning. Naloxone is a known non-selective inhibitor of the opioid receptors. I 
sought determine whether naloxone abolishes the protective effects of RIPC or 
RPostC in an attempt to identify a role for circulating opioids in the transfer of 
protection by remote conditioning. 
In chapter 5, I investigated the role of components of the autonomic nervous system 
in RIPC and RPostC. Using a human in vivo model of endothelial IR, a previous 
study in this laboratory showed that complete autonomic blockade with trimetaphan 
abolished the protective effects in the early and late phases of RIPC (187). I sought 
to determine the effect of alpha adrenergic and cholinergic nervous blockade on 
RIPC and RPostC using phentolamine and atropine respectively. 
Chapter 6 entailed investigations into the role of oral inorganic nitrate, as an 
endogenous source of NO during IR injury in humans. This is in recognition of the 
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role of an alternative pathway of NO generation during IR injury (196). I sought to 
determine whether oral inorganic nitrates in the form of beetroot juice and KNO3 
tablets protected against endothelial IR injury. 
The above aims are a component of a larger investigation of the mechanistic 
aspects of ischaemic protection in humans. This will build on the data in animal 
models and identify potential pharmacological targets in humans, as a prelude to 
clinical trials in patients. 
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Chapter 2 
 
General methods 
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2.1 The human forearm model of IR injury 
By inflating a blood pressure cuff to a suprasystolic pressure it is possible to achieve 
ischaemia in the forearm. The ability to measure IR-induced endothelial dysfunction 
in the human forearm has enabled the mechanistic assessment of different 
protective strategies. Ischaemic protection by IPC, PostC and remote conditioning 
has previously been investigated using the human forearm endothelial IR injury 
model (124, 169, 233). 
 
2.1.1 Induction of IR injury 
Ischaemia of the non-dominant arm (plethysmography studies)/right arm (vascular 
ultrasound studies) was achieved by inflating a 12cm or 9cm wide blood pressure 
cuff respectively, placed around the upper arm to a pressure of 200 mm Hg for 20 
min. Thereafter, 20 minutes of reperfusion allowed restoration of baseline diameter 
and blood flow as described previously (53, 124, 171, 187, 233).  
 
2.1.2 Induction of ischaemic preconditioning (IPC) 
IPC was induced by inflating a 9cm-wide blood pressure cuff placed around the 
upper part of the right (index) arm. The cuff was inflated to 200 mm Hg for 5 minutes 
(ischaemia of the arm), followed by a 5-minute deflation (reperfusion). This 
constituted a conditioning cycle and 3 cycles were used in advance of IR, as 
described previously (233). 
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2.1.3 Induction of ischaemic postconditioning (PostC) 
PostC was induced by short periods of intermittent reperfusion to the ischaemic arm 
in the first 60 seconds of reperfusion (124). At the end of the 20 minute period of 
index ischaemia, the upper arm cuff was deflated for 10 seconds (allowing 
reperfusion), after which the cuff was again inflated to 200 mmHg for 10 seconds 
(restoring ischaemia). The alternating deflation/inflation cycle was repeated 3 times 
(1 minute total duration), after which continuous reperfusion of the arm occurred. 
 
2.1.4 Induction of remote preconditioning (RIPC) 
RIPC was induced by inflating a 9cm-wide blood pressure cuff placed around the 
upper part of the contralateral arm (ArmRIPC) or 12cm blood pressure cuff around 
the upper part of the thigh (LegRIPC). The cuff was inflated to 200 mm Hg for 5 
minutes (ischemia of the arm), followed by a 5-minute deflation (reperfusion). This 
constituted a conditioning cycle and 3 cycles in the arm or 2 cycles in the leg were 
used in advance of IR, as described previously (171, 187). 
 
2.1.5 Induction of remote postconditioning (RPostC) 
RPostC was induced by inflating a 12cm-wide blood pressure cuff placed around the 
upper part of the thigh. The cuff was inflated to 200 mm Hg for 5 minutes (ischemia 
of the arm), followed by a 5-minute deflation (reperfusion). This constituted a 
conditioning cycle and 2 cycles were used during the 20 min index ischemia, as 
described previously (171). 
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2.2 Measurement of endothelial function 
It is now well established that the single layer of cells lining blood vessels, termed 
endothelium, subserves several important functions that maintain the integrity of the 
cardiovascular system. In view of its varied function it is perhaps not surprising that 
no single measure describes all aspects of endothelial function. In addition, 
endothelial function may vary depending on the vascular bed, disease condition or 
even the type of flow (eg laminar versus turbulent) to which the endothelium is 
exposed (234, 235).  However the vasomotor function has been easiest to measure 
in humans. In response to certain physical and chemical stimuli the endothelium 
releases NO which causes blood vessels to dilate (236-238). The degree of 
vasodilatation and/or blood flow can be measured and is an assessment of 
endothelial function. This can be done by invasive (venous occlusion 
plethysmography; intravascular coronary ultrasound) and non-invasive 
(brachial/radial artery FMD; pulse wave analysis, pulse amplitude tonometry) 
techniques.  In this thesis, endothelial function assessment has been performed in 
two vascular beds – conduit vessel (brachial artery) and resistance vessels.  
 
2.2.1 Assessment of conduit vessel endothelial function  
By using vascular ultrasound, the endothelial response to shear stress (increased 
blood flow) can be measured. This phenomenon is known as flow mediated 
dilatation (FMD) and is used to assess endothelial function in conduit arteries such 
as the brachial or radial artery. The mechanisms that underlie an increase in NO 
bioactivity in response to shear stress include increased levels of calcium which 
occurs as a result of the opening of calcium-activated potassium channels (236). 
This leads to increased eNOS activity; subsequent increased NO generation and 
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vasodilatation. The increase in vessel diameter is measured using vascular 
ultrasound.  FMD in the forearm is largely NO- dependent because administration of 
a NOS inhibitor abolishes FMD (238, 239). Factors which affect the magnitude of 
FMD include temperature, food, vasoactive drugs, physical exercise, sympathetic 
stimuli such as acute exercise and mental stress, phase of the menstrual cycle and 
the magnitude of the blood flow stimulus (236). These factors should be taken into 
account when performing FMD studies.  
 
2.2.1.1 Subject preparation 
FMD studies in this thesis were performed at the Vascular Physiology Unit, Institute 
of Child Health, UCL and the Clinical Research Facility UCL Hospital. Studies were 
performed on healthy, non-smoking volunteers (18-45 years of age) in a quiet, 
temperature-controlled laboratory (24oC to 26oC). Volunteers were asked to refrain 
from caffeine-containing drinks and fatty meals for 4 hours prior to each study and 
refrain from excessive exercise for 24 hours prior to each study. The exclusion 
criteria were a history of any illness, volunteers taking systemic medication, 
pregnancy or age <18 years or >45 years. Studies repeated in same volunteers 
were at least 7 days apart and in a random order sequence. All protocols were 
undertaken after review by an NHS research ethics committee. 
 
2.2.1.2 Experimental technique 
Subjects were positioned comfortably (Fig 2.1) and brachial artery flow mediated 
dilatation (FMD) of the right arm was assessed. Reactive hyperaemia of the forearm 
(achieved by means of the FMD cuff) was used as a stimulus to increase blood flow 
in the brachial artery resulting in brachial artery dilatation (239).  A B-mode 
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ultrasound scan of the brachial artery was obtained in longitudinal section between 5 
and 10 cm above the antecubital fossa with 7.0-MHz linear-array transducer [spatial 
resolution of 0.1 mm] (240) and a standard Acuson XP10 system. Longitudinal, 
ECG-gated, end-diastolic images were acquired every 3 seconds for offline analysis 
(Fig 2.2). Arterial diameter over a 1- to 2- cm segment was determined for each 
image using automatic B-mode edge-detection software (Brachial Tools, Medical 
Imaging Applications).  
 
 
 
 
Ischaemia 
Cuff 
FMD Cuff 
Adjustable 
Probe Holder 
Probe 
 78 
 
 
Fig. 2.1: These photographs show the subject positioning and  experimental set up during an FMD study. 
 
 
 
 
 
 
 
 
 
Fig 2.2: Image of longitudinal section of the brachial artery on ultrasound machine. 
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Blood flow was manipulated in the brachial artery by means of a 9-cm-wide 
pneumatic cuff (Scanmed, Moreton-in-Marsh, Gloucestershire, UK) placed around 
the forearm immediately below the antecubital fossa (FMD cuff). After 1 min of 
baseline flow, the cuff was inflated to 300 mm Hg for 5 minutes and then released, 
resulting in a brief episode of reactive hyperaemia. Brachial artery diameter changes 
in response to blood flow were assessed for a further 5 min. Blood flow velocity was 
continuously monitored by pulsed-wave Doppler. 
 
2.2.1.3 FMD calculation 
FMD in this thesis is expressed as peak percentage change in arterial diameter from 
baseline (Fig. 2.3). FMD may also be expressed as absolute change in arterial 
diameter. 
 
 
Fig. 2.3: FMD expressed as percentage change in brachial artery diameter from baseline at peak dilatation. 
 
 
2.2.1.4 Measurement of blood flow 
Blood flow velocity was measured using the pulsed wave doppler flow signal [Figure. 
2.2]. This is the velocity-time profile for a single cardiac cycle and is displayed as a 
spectral doppler curve. The area under the curve of the velocity-time profile is the 
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velocity-time integral [VTI = velocity (m/s) x time (s)] and approximates to the 
average distance, measured in metres, travelled by a pulse of blood during one 
cardiac cycle, typically at rest 0.01 – 0.05 m [Figure 2.4]. 
    
           
 
 
 
 
 
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4: (a) Blood flow / time profile; velocity time integral (VTI). (b) VTI and dilatation as a function of time 
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Blood flow is that volume of blood that passes a point in a specified period of time. 
Assuming that we can approximate a section of artery to a cylinder, the calculation 
of the blood flow volume will be as follows:  
 
Volume / cardiac cycle = artery cross-sectional area x average distance 
travelled by pulse = πr2 (t) ∫ v(t) dt, 
(r(t) = the measured instantaneous vessel radius and v(t) = the instantaneous 
blood velocity) 
The Doppler signal is measured at an angle of approximately 70º to the axis of the 
blood vessel, giving ∫ v(t) dt = cos 70º x measured VTI. Therefore, 
 
Volume / cardiac cycle = cos 70º.πr2 (t).VTI 
Volume per minute is calculated by multiplying this value by heart rate (HR). 
Volume / min= HR cos 70º.πr2 (t).VTI. 
 
If the heart rate, the doppler angle of incidence and arterial diameter (2 x arterial 
radius) are assumed to remain constant during the period of the study, VTI can be 
considered proportional to volume flow per minute. Measurement of the radius for 
the period of peak flow (up to 30 seconds after cuff release) confirms that there is 
minimal change in arterial diameter at this time. Furthermore, during the same time 
period heart rate and doppler angle are also constant. Thus a valid conclusion is that 
peak volume following cuff release coincides with peak VTI. A small change in 
arterial diameter will introduce an error into the assessment of flow based on VTI. 
This error may be calculated as follows: 
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Volume / min = HR (t=0) cos 70º.πr2 (t=0).VTI [1 + 2∆r/ r (t=0)] 
 
r (t=0) is the arterial radius at the time when the blood pressure cuff is released and 
it is equal to the radius of the artery prior to forearm ischaemia. Therefore fractional 
error is typically (2∆r / r (t=0)) and is maximal at about t=60s (approximately 6%). 
However, for the 30 seconds following cuff release this is negligible, as the arterial 
radius remains almost constant and approximately equal to r (t=0).   
Taking the above into account, the following formula can be used to calculate peak 
volume flow per minute during reactive hyperaemia: 
 
Volume / min (peak) = HR(at time of peak VTI) cos 70º.πr(t=0)2.VTI(peak) 
 
2.2.1.5 Data presentation of blood flow 
For studies in this thesis, baseline and peak VTI were calculated and the ratio of 
peak to baseline absolute volume flow per minute was determined using the 
following formula:  
 
Volume / min (peak)          HR (at time of peak VTI).VTI (peak) 
 Volume / min(baseline)               HR(baseline).VTI(baseline) 
 
This formula is based on the assumption that r(t=0) is approximately equal to 
r(baseline). In all of the studies in this thesis there were no significant changes in 
heart rate. However to avoid the risk of confounding effects of changes in heart rate 
affecting the measurement of the flow stimulus, heart rate values were recorded at 
= 
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the same time as the VTI measurements at baseline and peak hyperaemia and 
incorporated into the calculation of the volume flow per minute ratio. 
 
2.2.1.6 Accuracy and reproducibility of the technique 
The validity of any measuring technique depends on its degree of accuracy and 
reproducibility. Error arises when the same observer makes repeated measures 
(intraobserver error) and when different observers make the same measures 
(interobserver error). To enable the detection of a reliable effect of an intervention, 
knowledge of the reproducibility is essential. FMD has a high degree of 
reproducibility as evidenced by studies which show a low coefficient of variation (CV) 
(241, 242). A pre-requisite to reproducibility of FMD is standardisation of the 
technique and operator training both of which are part of the standard operating 
procedures within the laboratories where these studies were performed. Comparison 
of FMD responses in a single subject measured on multiple occasions or between 
groups of subjects is possible provided that there are no major differences in basal 
blood flow, or arterial diameter. Image analysis is another factor that influences the 
reproducibility of FMD. B mode edge detection software was used for analysis in this 
thesis and compared with an alternative method of analysis (A-mode wall tracking 
(A-WT) (Vadirec, Medical Systems Arnhem, Oosterbeek, the Netherlands), has a 
lower coefficient of variation (242).  
Having performed detailed assessments of brachial artery FMD, Donald et al have 
expressed reproducibility of FMD as the percentage of coefficient of variation (CV) = 
[(standard deviation of the paired differences/the overall mean)/√2] x 100 (242). 
Reproducibility of FMD in this thesis has been presented in a similar manner. I 
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assessed intraobserver variability by performing two sequential scans on 8 subjects 
at least 72 hours apart. Interobserver variability was assessed by performing 
repeated FMDs in 8 subjects on two separate days at least 72 hours apart. One of 
the scans was performed by an experienced vascular sonographer (Ann Donald) 
and the other by me.  
My intraobserver CV was 6.24%; n=8 and interobserver CV was 7.6%; n=8. These 
are comparable to the published data for FMD CV of 7.1% for adults and 6.3% for 
children (241).  
 
2.2.2 Assessment of resistance vessel endothelial function  
Forearm venous occlusion plethysmography measures endothelial function in 
resistance vessels in response to chemical stimuli. Local administration of 
endothelium dependent vasodilator drugs such as acetylcholine (ACh) and 
bradykinin increases forearm blood flow which is an index effect of these drugs on 
the endothelium (237). By so doing, the endothelial function in forearm resistance 
vessels can be indirectly assessed. Forearm plethysmography is based on the 
principle that if venous return from the arm is obstructed and arterial inflow 
continues, the result is forearm swelling at a rate proportional to the arterial inflow 
(237, 243). The rate of swelling is measured as a change in the forearm 
circumference which reflects a change in forearm blood flow (FBF). FBF is 
predominantly in skeletal muscle, so the hands are excluded during measurements 
because blood flow in the hand is predominantly through the skin. Another reason 
for excluding the hand is a high proportion of arteriovenous shunts (243). 
Absolute values of basal blood flow in the forearm may vary with the time of day or 
sympathetic tone but should not alter the ratio of flow in the two arms or the 
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percentage response to drugs calculated from the ratio (237, 243). The presence of 
a control arm (contralateral arm) for each study is an advantage of the technique. To 
minimise variability, studies should be undertaken in a quiet, temperature-controlled 
environment and results expressed as a ratio of flow in the two arms.  
 
2.2.2.1 Subject preparation 
Venous occlusion plethysmography studies in this thesis were performed in the 
Clinical Pharmacology Clinical Laboratory, and subsequently in the Clinical 
Research Facility, University College Hospital London. Other aspects of subject 
preparation were as for FMD studies highlighted in section 2.2.1.1. 
 
2.2.2.2 Experimental technique 
Subjects were positioned comfortably (Fig 2.5) and bilateral forearm blood flow was 
measured by means of mercury-in-silastic strain gauge plethysmography, as 
described previously (233, 237, 243).  The brachial artery of the non-dominant arm 
was cannulated with a 27-gauge needle (Cooper’s Needle Works, Birmingham, UK) 
under aseptic technique using 2ml of 2% lidocaine (subcutaneous) for anaesthesia 
(Fig. 2.6). Drugs were administered in saline (0.9% [wt/vol] sodium chloride) and 
infused at a rate of 0.5ml/min. During recording periods, the hands were excluded 
from the circulation by inflation of the wrist cuffs to 200 mm Hg. Forearm blood flow 
in response to the endothelium-dependent dilator acetylcholine (ACh; 25, 50 and 
100nmol/min; each dose for 3 minutes) was measured 15 minutes after cannulation 
to establish baseline endothelial function. For some studies the response to the 
endothelium-independent dilator, glyceryl trinitrate (GTN; 4, 8 and 16 nmol/min; each 
dose for 3 minutes) was determined. 
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Fig 2.5: Experimental set up during venous occlusion plethysmography 
 
 
 
 
Fig 2.6: Needle positioning during venous occlusion plethysmography 
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2.2.2.3 Data analysis 
Calibration of the strain gauges occurred at the start of each experiment for each 
subject. The mean slope of the last four recordings (over a minute duration) during 
the infusion of normal saline and each subsequent drug infusion (the last minute of 
recording of each dose of the infused drug) was used for analysis. Forearm blood 
flow was expressed as ml (flow)/100 ml (forearm volume)/minute. In this thesis, data 
were expressed as the percentage change in ratio of blood flow (infused/non-infused 
arm). This method enabled adjustment for non-specific changes that may change 
resting blood flow (243). Dose-response curves of percentage change in ratio of 
blood flow (infused/non-infused arm) against dose of vasodilator (ACh or GTN) were 
obtained. Other possible methods of expression of this data are as absolute blood 
flow, or as percentage change in absolute blood flow.  
 
2.2.2.4 Accuracy and reproducibility of technique 
Blood flow measured by strain gauge plethsymography correlates with that 
measured using doppler ultrasound (244).  However factors such as mental arousal, 
sympathetic activity and ambient temperature can contribute to significant difficulty in 
interpretation of forearm blood flow (FBF) measurements. As a result of 
considerable intra-individual variation in a single limb (coefficient of variation – CV 
>30%), FBF measurements are performed in both forearms and expressed as 
changes in relation to the other (FBF ratio of intervention to control forearms) (245). 
This eliminates the confounding effects of background changes in FBF and reduces 
the variability of the technique (CV 20%). 
In this thesis, intra-individual variation in baseline FBF ratio was assessed in 13 
subjects who had repeated studies between three and seven times on separate 
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occasions. The mean CV for baseline FBF was 24.4%; n=13. After vasodilatation 
with acetylcholine (25, 50, 100nmol/min) the mean CV in dose response increased 
to 31.2%; n=13. These CVs compare with those obtained in other studies (245, 246). 
There is evidence that endothelial function measurements by plethysmography do 
not relate to arm length or circumference, but results may be affected by distal 
misplacement of the strain gauge (246, 247). 
 
2.3 Biochemical assays 
Biochemical assays in this thesis were performed at the department of clinical 
biochemistry, King’s College Hospital (KCH) under the supervision of Dr Roy 
Sherwood and Ms Tracy Dew for plasma beta endorphins and the Wolfson Institute 
for biomedical research, UCL in collaboration with Dr Adrian Hobbs for plasma 
nitrates and nitrites.  
 
2.3.1 Measurement of plasma beta endorphins  
Endogenous opioids are found in the brain, heart, sympathetic nerves and adrenal 
medulla.  They have been identified as important peptides in the triggering and/or 
mediation of ischaemic protection, particularly in the myocardium (248). There are 
three well characterised endogenous opioids (enkephalins, dynorphins, and 
endorphins) and they interact with G-protein coupled receptors (GPCRs) opioid 
receptors (δ, µ, κ) to exert their biological effects (249-251). 
Beta endorphin is a 31 amino acid peptide first isolated from camel pituitary (252).  It 
is derived from the C-terminal fragment of a 31kDa precursor molecule known as 
proopiomelanocortin (POMC) and has been found in a variety of tissues including 
brain, heart, adrenal gland and peripheral nerves (253).  Historically, measurement 
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of plasma levels of beta endorphin was performed by immunologic reactions which 
involved radioisotope antigen markers (254, 255). Although still used today, this 
laboratory technique [radioimmunoassay (RIA)] is fraught with problems of safety, 
complicated set up procedures and inconvenient storage, handling and disposal 
techniques. More recently, enzyme linked immunosorbent assay (ELISA), which has 
the advantage of simplicity and ease of use, has been used as a sensitive assay for 
beta endorphins (254, 255). Importantly, a good correlation (r=0.95) exists between 
ELISA and RIA for quantitative determination of beta endorphins in plasma (256)  
 
2.3.1.1 Beta endorphin ELISA 
This assay is based on the principle of competitive inhibition enzyme immunoassay 
which was first developed as a two step ELISA technique and had a sensitivity of 10 
picograms (3 femtomoles) per well (254). Based on this principle, other researchers 
have subsequently developed more sensitive ELISA assays for beta endorphin 
detection in humans (255). 
Beta endorphin is a relatively small peptide and competitive inhibition assays are 
often used for small analytes because of the risk of steric hindrance which may 
occur with other techniques that entail the binding of two antibodies to the molecule 
at the same time, as in the monoclonal – polyclonal sandwich immunoassay.  
The non-specific binding sites of a secondary antibody, on a pre-coated microtitre 
immunoplate, are blocked. This enables the secondary antibody to bind to the Fc 
fragment of the primary antibody (beta endorphin antibody) whose Fab fragment will 
be competitively bound by both biotinylated beta endorphin and beta endorphin 
standard or targeted beta endorphin in the sample. The biotinylated beta endorphin 
is able to interact with streptavidin-horseradish peroxidise (HRP) which catalyzes the 
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substrate solution composed of 3, 3', 5, 5'- tetramethylbenzidine (TMB) and 
hydrogen peroxide to produce a blue coloured solution. This enzyme substrate 
reaction is stopped by hydrogen chloride and the solution turns to yellow. The 
intensity of the yellow is directly proportional to the amount of biotinylated beta 
endorphin – HRP complex but inversely proportional to the amount of beta 
endorphin in standard solutions or samples. This is due to the competitive binding of 
the biotinylated beta endorphin and the beta endorphin in standard solutions or 
samples to the beta endorphin antibody (primary antibody). A standard curve of a 
beta endorphin with known concentration can then be established accordingly. The 
beta endorphin with unknown concentration in samples can be determined by 
extrapolation to this standard curve (ref: MD biosciences® beta endorphin ELISA 
protocol; www.mdbiosciences.com). 
 
2.3.1.2 Preparation of plasma 
Venous blood was collected in EDTA tubes containing 312µl aprotinin (0.6 TIU/ml of 
blood) and shaken gently. This was to prevent clotting and degradation of proteins 
by proteinases.  4-mls of blood at specified time points during RIPC were collected 
(details of experimental protocol in chapter 4). Venous blood samples were 
centrifuged (3000rpm for 15 minutes at 4°C), to obtain plasma. The plasma samples 
were aliquoted and stored at -80°C until laboratory analysis was performed within 
one month. Plasma samples were transported to KCH on dry ice.  
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2.3.1.3 Assay procedure 
All reagents were prepared as recommended by the assay manufacturers. Microtitre 
well plate (Fig 2.8) A-1 was left empty as a blank and 50 µL assay buffer was added 
into B-1 as total binding.  
50 µL standard (1.0 µg of human beta endorphin; Lyophilized) + positive control 
(0.4-0.6 ng/ml of human beta endorphin lyophilized) were added to the remaining 
wells in duplicate. 25 µL of primary antiserum (rabbit anti beta endorphin IgG) was 
added into each well except the blank. 25 µL of biotinylated beta endorphin was 
added into each well. The well plates were then covered and incubated for 2 hours 
at room temperature. Thereafter each well (except blank) was washed 6 times with 
300 µL assay buffer and blotted dry. 100 µL HRP solution was added to each well 
(except blank). The wells were then covered and incubated at room temperature. A 
repeat wash with assay buffer (as above) was performed and then 100 µL of 
substrate solution (TMB) was added to each well (including blank). The wells were 
covered and incubated for 1 hour at room temperature.  Finally, 100 µL 2N HCl was 
added to each well (including blank) and absorbance at 450nm was read by a 
microplate reader.  
 
2.3.1.4 Data analysis 
The concentration of beta endorphin in a sample was determined by reference to the 
standard curve and expressed in ng/ml. 
 
2.3.1.5 Accuracy and reproducibility of the assay 
The sensitivity of the assay is 0.15 ng/ml  (range 0.15 –1.96ng/ml) and is 
comparable to other beta endorphin ELISA assays used by other researchers (254, 
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255).  Intra-assay variation of <5-10% and inter assay variation of <15%. Cross 
reactivity specificity for human beta endorphin was 100%. 
 
 
2.3.2 Measurement of plasma nitrates and nitrites  
The reduction of nitrite and nitrate to NO at room temperature is facilitated by an 
acidic milieu containing vanadium III. However at room temperature nitrates are only 
very slowly reduced. Heating to temperatures of 80 – 90 ºC enables the rapid 
reduction of both nitrite and nitrate (257). This forms the basis of the 
chemiluminescence detector-based method for trace nitrites and nitrates in aqueous 
samples. Earlier chemiluminescence methods employed glacial acetic acid and 
potassium Iodide to reduce nitrite to nitric oxide.  However this only resulted in 
reduction of nitrite but not nitrate, thus providing a method to determine nitrite 
concentration in the large excess of nitrate in plasma (258).The chemiluminescence 
analysis method is used in environmental analyses and human fluids where trace 
nitrite and nitrate data are needed. Other methods to measure nitrite levels in 
plasma include flow injection analysis (FIA) and high pressure liquid chromatography 
(HPLC). However ozone chemiluminescence is more sensitive to trace quantities of 
NO, making it the method of choice when extremely low concentration of nitrites 
must be quantified in a complex matrix and sample volumes are limited (258, 259).  
 
2.3.2.1 Ozone chemiluminescence analysis of NOx 
Acidic vanadium III at 98 ºC quantitatively reduces both nitric acid and nitrate to NO. 
The released NO is carried by inert gas to a detector where it reacts with ozone to 
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produce a chemiluminescence signal proportional to the concentration and this is 
quantified (258). 
 
2.3.2.2 Preparation of samples 
Venous blood samples were collected from a large superficial arm vein, at specified 
time points (see chapter 6) and transferred into heparin tubes containing 5 IU/ml of 
blood). The samples were centrifuged at 1300G at 40C for 15 minutes. The plasma 
supernatant was separated from the red blood cells and both samples were stored 
at - 80 ºC until analysis. The blood sampling and centrifugation was performed 
without delay to prevent the nitrite from rapidly reacting with haemoglobin to form 
nitrate under oxygenated conditions or iron-nitrosylhaemoglobin under de-
oxygenated conditions (259). 
 
2.3.2.3 Experimental procedure 
Prior to ozone chemiluminescence, plasma samples were filtered using Microcon® 
Ultracel YM (3 kDa) filters (Millipore Corporation, Billerica, USA) and then [nitrate] 
and [nitrite] in the filtrate determined (260).  Samples and standards containing nitrite 
and nitrate were first reduced to NO, which was then quantified using a NO analyzer 
(NOA 280, Sievers, Boulder, USA). To determine total [nitrite] and [nitrate] (NOx), 
samples were added to 0.1 mol/L vanadium (III) chloride in 1M hydrochloric acid 
refluxing at 90°C under nitrogen. Nitrite concentrations were determined by addition 
of samples to 1.5% potassium iodide in glacial acetic acid under nitrogen at room 
temperature.  Concentrations of nitrate were calculated by subtraction of [nitrite] 
from NOx values. 
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2.3.2.4 Data analysis and accuracy 
The sensitivity of the ozone chemiluminescence is 1±1nmol/L with a coefficient of 
variation of 5%. Plasma concentrations (µmol/L) of nitrate and nitrite were 
determined after construction of standard curves. 
 
2.4 Drugs and reagents 
Acetylcholine (ACh) was obtained from Merck Biosciences, Nottingham, UK; 
Lidocaine Hydrochloride from Antigen Pharmaceuticals, Roscrea, Ireland; 0.9% 
sodium chloride from Baxter Healthcare, Norfolk, UK; Glibenclamide (Glib) from 
APS, Eastbourne, UK; Glimepiride (Glim) from Alpharma, Barnstable, UK; 
Ciclosporin (Sandimmun® ) from Novartis Pharma, UK;  Naloxone from CP 
Pharmaceuticals Ltd, Wrexham, UK; Phentolamine from Alliance Pharmaceuticals 
Chippenham, Wiltshire, UK; Atropine from Antigen Pharmaceuticals, Roscrea, 
Ireland; Potassium nitrate from Martindale Pharmaceuticals, UK; Potassium Chloride 
from Martindale Pharmaceuticals, UK; Beetroot juice from Planet Organic; Aprotinin 
was obtained from Nordic Pharma, UK. 
 
 
2.5 Calculations and statistical analysis 
All data were analysed with GraphPad prism version 4.0 (GraphPad Software, USA) 
and expressed as mean±SEM. For conduit vessel studies, data were compared 
using a paired t test or ANCOVA as appropriate.  For resistance vessel studies, ACh 
dose-response curves were constructed and the area under the dose-response 
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curve (AUC) calculated. Comparisons before and after an intervention were made 
using paired 2-way ANOVA or ANCOVA as appropriate.  
A repeated measure ANCOVA was used to compare post-IR values between 
interventions. Adjustment for baseline FMD and AUC of the baseline dilator 
response to ACh values was made by including the pre-IR values as a baseline co-
variate. Post hoc comparisons between pairs of interventions were performed and 
adjustment for multiplicity was made using the Scheffe’s test. In all cases, a value of 
P<0.05 was considered statistically significant. The D’Agostino-Pearson normality 
test was used to check for ANCOVA normality assumption. 
Sample size calculations used prior estimates of FMD (mean 8.6%, within individual 
SD of 2.3) and resistance vessel dilatation to ACh (mean area under the dose-
response curve to ACh 13,000 units, within subject SD of 6000). To detect a 50% 
reduction in dilatation, at an α value of 0.05 and a β level of 0.8, required n=7 (FMD) 
and n=16 (plethysmography). 
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Chapter 3 
 
The role of the KATP channel and the 
mitochondrial permeability transition pore in 
the mechanism of postconditioning in humans 
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3.1 Introduction 
Ischaemic postconditioning (PostC) elicited by intermittent restoration of blood flow 
at the onset of reperfusion and has been proven to be effective in reducing 
experimental and clinical IR injury (see section 1.8). PostC is mechanistically similar 
to ischaemic preconditioning (IPC); however IPC is activated by brief periods of non-
lethal ischaemia in advance of an injurious ischaemic insult. IPC and PostC cause 
similar degrees of tissue protection in experimental settings of IR injury, and these 
observations suggest that much of reversible tissue damage caused by IR injury 
occurs early in the reperfusion phase. Cardiovascular events are unpredictable and 
this makes PostC an attractive intervention, especially in acute ischaemic 
syndromes where there is a degree of mechanical control over the schedule of 
reperfusion. This has been successfully demonstrated in clinical studies of PostC in 
ST-segment elevation myocardial infarction (see section 1.8.5).  
The control of reperfusion in the majority of acute ischaemic syndromes has 
remained technically challenging. Pharmacological activation of PostC mechanisms 
could be a useful adjunct to reperfusion therapy in other domains. Much is known of 
the mechanism of PostC in animal models, with an important role identified for 
mitochondria, through the opening of the mitochondrial KATP channel associated with 
closure of the mitochondrial permeability transition pore (mPTP) (145, 155, 156). In 
this chapter, I sought to determine a role for KATP channels in PostC and a role for 
inhibition of the mitochondrial permeability transition pore at reperfusion in ischaemic 
protection. I have used an inhibitor of the mPTP (ciclcosporin) and KATP channel 
blockers with different tissue specificity (glibenclamide and glimepride) to achieve 
this. 
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3.2 Methods 
 
3.2.1 Subjects 
One hundred and thirty nine studies were performed on 24 healthy, non-smoking 
volunteers aged 18-45 years. Of these, 9 were recruited to the FMD studies and 17 
recruited to the venous occlusion plethysmography studies receiving interventions 
based on KATP channel blockade. 11 volunteers were recruited to the venous 
occlusion plethysmography studies receiving interventions based on mPTP 
blockade.  
 
3.2.2 Assessment of Conduit Vessel Endothelial Function 
Brachial artery flow mediated dilatation (FMD) of the right arm was assessed, as 
described in section 2.2.1. 
 
3.2.3 Assessment of Resistance Vessel Endothelial Function 
Bilateral forearm blood flow was measured using mercury-in-silastic strain gauge 
plethysmography, as described in section 2.3.1  
 
3.2.4 Induction of IR injury 
Ischaemia of the non-dominant arm (plethysmography studies)/right arm (vascular 
ultrasound studies) was achieved as described in section 2.1.1. Uninterrupted 
reperfusion occurred on cuff deflation. 
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3.2.5 Induction of Postconditioning 
PostC was induced by short periods of intermittent reperfusion to the ischaemic arm 
in the first 60 seconds of reperfusion as described in section 2.1.3. The alternating 
deflation/inflation cycle was repeated 3 times (1 minute total duration), after which 
continuous reperfusion of the arm occurred. 
 
3.3 Experimental Protocols 
 
3.3.1 Effect of IR on Endothelial Function 
To determine the effect of IR on endothelial function (EF), brachial artery FMD and 
forearm blood flow in response to ACh (Figure 3.1a) was assessed before ischaemia 
(baseline) and at 20 minutes after reperfusion. It has previously been demonstrated 
that this protocol results in endothelial dysfunction in the brachial artery and forearm 
resistance vessels (53, 124, 169, 171, 187, 233). 
 
3.3.2 Effect of IR on vascular smooth muscle function 
To determine the effect of IR on smooth muscle function in resistance vessels 
forearm blood flow in response to GTN was assessed before ischaemia and at 20 
minutes after reperfusion (Figure 3.1b). Previous studies in this laboratory have 
demonstrated that this protocol did not result in vascular smooth muscle dysfunction 
in conduit vessels (187, 261). 
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3.3.3 Effect of postconditioning on endothelial IR Injury 
To establish that protection against endothelial IR can be achieved by modifying 
reperfusion, PostC was induced in the same group of volunteers. The PostC 
schedule was applied at the onset of reperfusion, immediately after index ischaemia 
(Figure 3.1c) 
 
3.3.4 Mechanism of protection by PostC in humans: Role of KATP channels 
The effect of KATP channel blockade on PostC was investigated using the 5mg oral 
glibenclamide [non-selective KATP channel blocker] and 1mg oral glimepiride 
[pancreas-selective KATP channel blocker] (262-264 ). Drugs were administered 45 
minutes before assessment of baseline endothelial function of conduit and 
resistance vessels (Figure 3.2a) (171, 233). This was followed by 20 minutes of arm 
ischaemia, PostC and a repeat assessment of endothelial function. To exclude a 
direct vascular effect of either KATP channel blocker on the endothelial response to 
IR injury, endothelial function was determined before and after IR injury in the 
presence of glibenclamide (n=4) or glimepiride (n=5), (Figure 3.2b). In all studies a 
high-carbohydrate meal (59g carbohydrates; 15g fat; 2.4g protein; 386 Kcal) was 
given immediately and 3 hours (115g carbohydrates; 50g total sugars; 20g fat; 27g 
protein; 750 Kcal) after the administration of glibenclamide and glimepiride (171, 
233). Blood glucose was monitored throughout the study. 
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Figure 3.1: Protocol of studies to determine the effect of PostC on endothelial IR-injury (a) Endothelial 
function (EF) in the brachial artery and forearm resistance vessels was assessed before 20 minutes of arm 
ischaemia (I) and at 20 minutes of reperfusion (R). (b)The vascular smooth muscle function (SMF) in the forearm 
resistance vessels was assessed before and after IR injury. The effect of PostC was determined (c) by applying 
3 cycles of 10 seconds of arm reperfusion and 10 seconds of arm ischaemia. 
 
 
a. 
                                                                                      
 
 
b. 
 
 
 
Figure 3.2: Protocol of studies to determine the role of KATP Channels in PostC (a) To determine the 
effect of Glibenclamide on PostC; Baseline EF was assessed in the brachial artery (FMD) and resistance vessels 
(dose response to ACh). 3 cycles of PostC were applied after 20 minutes of ischaemia of the arm (at the onset of 
reperfusion) in the presence of oral glibenclamide 5mg which was administered 45 minutes before IR. EF was 
reassessed at 20 minutes of reperfusion. To determine the effect of glimepiride on PostC; Baseline EF was 
assessed in the brachial artery and resistance vessels. 3 cycles of PostC were applied after 20 minutes of 
ischaemia of the arm in the presence of oral glimepiride 1mg which was administered 45 minutes before IR. EF 
was reassessed at 20 minutes of reperfusion. (b) Experiments to exclude any direct effects of glibenclamide or 
glimepiride on endothelial response to IR injury.  
 
 
3.3.5 Effect of inhibition of the mPTP on endothelial IR Injury 
In cohort 2 (n=11), the role of the mPTP in PostC was assessed using ciclosporin 
(non-selective mPTP blocker) administered intra-arterially at reperfusion. Baseline 
response to ACh was assessed before and after IR injury as above (Figure 3.3a). 
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I (20 minutes) R (20minutes) 
I  R 
20 minutes  20 minutes 
On a separate study day, subjects underwent IR injury, during which ciclosporin 
(Sandimmun-Novartis; 0.6µmol/min), was administered during the last 2 minutes of 
ischaemia and the first minute of reperfusion (Figure 3.3b). After 20 minutes of 
reperfusion the response to ACh was repeated. To assess for a direct effect of 
ciclosporin on endothelial function, the protocol was repeated without IR (Figure 
3.3c). 
   
a.                              
 
 
b.                       
 
 
c.                      
 
          
 
 
Figure 3.3: Protocol of studies to determine the role of the mPTP in PostC. (a) Endothelial function (EF) 
in the forearm resistance vessels was assessed before 20 minutes of arm ischaemia (I) and at 20 minutes of 
reperfusion (R) (b) Baseline EF was assessed in the resistance vessels (dose response to ACh). To determine if  
mPTP inhibition mimics, the mPTP inhibitor ciclosporin (0.6µmol/min) was infused into the brachial artery during 
the last 2 minutes of ischaemia and the first minute of reperfusion (3 minutes in total). EF function was 
reassessed at 20 minutes of reperfusion.  
 
 
3.4 Calculations and Statistical Analysis 
See section 2.5 of chapter 2. 
 
3.5 Results 
All subjects tolerated the procedure. There was no significant difference in blood 
glucose between the glibenclamide- and glimepiride- treated subjects (Figure 3.4). 
Symptomatic hypoglycaemia was treated in two subjects in the glibenclamide group 
and one subject in the glimepiride group. There were no effects on blood pressure, 
EF EF 
 
Ciclosporin (3 minutes) 
EF EF 
 
          Ciclosporin (3 minutes) 
EF EF 
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heart rate, baseline brachial artery diameter or FMD flow stimulus during reactive 
hyperaemia (Table 3.1). 
 
 
 
 
 
 
Figure 3.4: Comparison of blood glucose concentration (mmol/l) in glimepiride and glibenclamide studies 
(p=0.2; Paired t test). 
 
3.5.1 Effect of IR on endothelial function 
IR reduced brachial artery FMD (7.1±0.9% before IR vs 2.8±0.4% after IR, P<0.001; 
Paired t test; n=9) [Figure 3.5a] and resistance vessel forearm blood flow (P=0.0014; 
ANOVA; n=17) [Figure 3.5c]. In the KATP studies, a significant correlation existed 
between baseline and post-IR values for FMD (Pearson’s r=0.6, P< 0.001) and 
vasodilator response to ACh AUC (Pearson’s r=0.7, P<0.0001). In the mPTP 
studies, a significant correlation existed between baseline and post-IR values for the 
vasodilator response to ACh AUC (Pearson’s r=0.7, P<0.001). These correlations 
justified using ANCOVA to adjust post-IR values for differences in baseline 
endothelial function (EF) between the different protocols, so that post-IR EF could be 
directly compared with greater statistical power (Tables 3.2, 3.4 and 3.5) 
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Table 3.1: Summary of blood pressure, heart rate, baseline brachial artery diameter and FMD flow stimulus 
(no units) during reactive hyperaemia. 
 
 
3.5.2 Effect of PostC on endothelial IR injury 
PostC prevented the IR induced endothelial dysfunction in the brachial artery FMD 
(6.8%±0.9% before IR+PostC vs 6.1±0.7% after IR+PostC, p>0.05; n=9) [Figure 
3.5b] and resistance vessels (P=0.38; n=16) [Figure 3.5d] 
 
3.5.3 Effect of IR on vascular smooth muscle function 
IR did not affect vascular smooth muscle function in the resistance vessel (P=0.92; 
n=9) [Figure 3.5e]. 
 IR Alone (n=9) 
IR+PostC 
(n=9) 
IR+PostC+Glib 
(n=9) 
IR+PostC+Glim 
(n=9) 
    Pre  
 
 Post  
 
  Pre  
 
 Post 
 
 Pre  
 
 Post 
 
  Pre  
 
 Post 
SBP  
(mmHg) 105±3 110±2 114±5 116±4 113±4 117±5 111±3 114±4 
DBP 
 (mmHg) 63±2 65±2 61±2 65±2 61±2 64±2 63±3 66±2 
HR (bpm) 67±5 66±5 65±3 63±3 64±3 64±3 66±3 65±2 
Baseline 
arterial 
diameter (mm) 
3.6±0.1 3.5±0.1 3.6±0.1 3.6±0.1 3.6±0.1 3.6±0.1 3.5±0.1 3.6±0.1 
Flow Stimulus 
(no units) 10.1±1.1 10.4±1.3 11.6±0.9 10.6±1.3 7.5±0.4 10.5±1.2 8.1±0.4 9.3±0.4 
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Figure 3.5: IR reduced endothelial function in the (a) brachial artery (FMD 7.1±0.9% pre-IR versus 2.8±0.4% 
post-IR; *P<0.001; n=9).  The IR induced endothelial dysfunction was prevented by PostC, in the (b) brachial 
artery (FMD 6.8%±0.9% pre- versus 6.1±0.7% post-IR+PostC; P>0.05; n=9). Similarly, IR induced endothelial 
dysfunction and in the (c) resistance vessels (*P=0.0014; n=18) and this was also prevented by PostC (d) 
(P=0.38; n=16). (e) IR did not affect vascular smooth muscle function in resistance vessels (P=0.92; n=9).  
BL=baseline; FBF=forearm blood flow. 
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3.5.4 Mechanism of Protection by PostC:  Role of KATP channels 
Glibenclamide abolished the protection induced by PostC against IR-induced 
endothelial dysfunction in the brachial artery (FMD 6.5±0.8% before IR + PostC + 
glibenclamide vs 3.1±0.4% after IR + PostC + glibenclamide, p<0.05; n=9) [Figures 
3.6a and 3.8] and resistance vessels (P=0.014; n=9) [Figures 3.6c and 3.8]. In 
contrast, glimepiride had no effect on PostC in the brachial artery (FMD 7.1±0.9% 
before IR + PostC + glimepiride vs 6.4±0.6% after IR + PostC + glimepiride, p>0.05; 
n=9) [Figures 3.6b and 3.8] or resistance vessels (P=0.56; n=10) [Figures 3.6d and 
3.9]. Neither glibenclamide (FMD 6.3±1.5 pre- versus 2.9±1.0 post-IR+Glib; P=0.03; 
n=4) [Figure 3.7a] nor glimepiride (FMD 6.9±1.1 pre- versus 3.6±0.7 post-IR+Glim; 
P=0.001; n=5) [Figure 3.7b] had any effect on the endothelial response to IR injury. 
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Figure 3.6:  In the presence of glibenclamide, the protection by PostC against IR was lost in the (a) brachial 
artery (FMD 6.5±0.8% pre- versus 3.1±0.4% post IR+PostC+Glib, †P<0.05; n=9) and (c) in the resistance 
vessels (P=0.014; n=9). In the presence of glimepiride the protection by PostC was preserved in the (b) brachial 
artery (FMD 7.1±0.9% pre- versus 6.4±0.6% post-IR+PostC+Glim, P>0.05; n=9) and (d) resistance vessels 
(P=0.56; n=10).  
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Figure 3.7: Endothelial response to IR injury was not affected by (a) Glibenclamide (FMD 6.3±1.5 pre- 
versus 2.9±1.0 post-IR+Glib; P<0.05; n=4) or (b) Glimepiride (FMD 6.9±1.1 pre- versus 3.6±0.7 post-IR+Glim; 
P<0.01; n=5).  
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Figure 3.8: Role of KATP channels in the mechanism of protection by PostC in the brachial artery. PostC 
prevented IR-induced reduction in FMD (post-IR FMD, 6.0±0.3%, n=9). The protective effects of PostC were 
abrogated by systemic glibenclamide (post-IR FMD, 3.3±0.2%, n=9). In the presence of glimepiride PostC 
prevented IR-induced reduction in FMD (post-IR FMD, 6.2±0.3%, n=9).  Post-IR values were adjusted for 
baseline FMD (ANCOVA). 
. 
 
 
 
Table 3.2: Summary of Baseline and Post-IR FMD data 
 
 
Study n 
Baseline 
FMD 
Post-IR 
FMD 
Post-IR 
 FMD (ANCOVA Adjusted) 
IR 9 7.1±0.9 2.8±0.4 2.6±0.4* 
IR+PostC 9 6.8±0.9 6.1±0.7 6.0±0.3† 
IR+PostC+Glibenclamide 9 6.5±0.8 3.1±0.4 3.3±0.2‡ 
IR+PostC+Glimepiride 9 7.1±0.9 
 
 
 
6.4±0.6                          6.2±0.3 
Data are expressed as mean±SEM. Post-IR FMD values were adjusted for baseline FMD by 
ANCOVA (Regression coefficient 0.56±0.13). For comparisons between the 4 groups, P 
values by ANCOVA were Scheffé adjusted. 
*P<0.001, IR vs IR+PostC and IR+PostC+Glimepiride  
†P<0.001, IR+PostC vs IR+PostC+Glibenclamide 
‡P<0.001, IR+PostC+Glibenclamide vs IR+PostC+Glimepiride 
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Table 3.3: Summary of Baseline and Post-IR dilator response to ACh AUC data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Role of KATP channels in the mechanism of protection by PostC in the resistance vessels. PostC 
prevented IR-induced reduction in the dilator response to ACh (Post-IR AUC 1.9±0.2 x 104; n=16). The protective 
effects of PostC were abrogated by systemic glibenclamide (Post-IR AUC 1.1±0.2 x 104; n=9). In the presence of 
glimepiride, PostC prevented the IR induced reduction in dilator response to ACh (Post-IR AUC 2.0±0.2 x 104; 
n=10). Post IR values were adjusted for baseline dilator response to ACh AUC (ANCOVA). AUC=area under 
curve; FBF=forearm blood flow. 
 
 
 
 
Study n 
Baseline 
AUC 
Post-IR 
AUC 
Post-IR 
 AUC (ANCOVA Adjusted) 
IR 17 2.1±0.4 1.5±0.2 1.0±0.1* 
IR+PostC 16 1.3±0.3 1.3±0.3 1.9±0.2† 
IR+PostC+Glibenclamide 9 2.4±0.7 1.5±0.3 1.1±0.2‡ 
IR+PostC+Glimepiride 10 2.1±0.6 
 
 
 
2.4±0.6                            2.0±0.2 
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Data are expressed as mean±SEM. Post-IR dilator response to ACh AUC values (x104) were 
adjusted for baseline AUC by ANCOVA (Regression coefficient 0.55±0.07). For comparisons 
between the 4 groups, P values by ANCOVA were Scheffé adjusted. 
 *P<0.001, IR vs IR+PostC and IR+PostC+Glimepiride  
 †P<0.001, IR+PostC vs IR+PostC+Glibenclamide 
 ‡P<0.01, IR+PostC+Glibenclamide vs IR+PostC+Glimepiride 
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3.5.5 Effect of inhibition of the mPTP on endothelial IR Injury 
 
IR reduced the vasodilator response to ACh (P=0.006; n=11) [Figures 3.8a and 
3.11]. Infusion of ciclosporin around the onset of reperfusion mimicked the protective 
effect of PostC (p=0.44; n=11) [Figure 3.8b and 3.11]. Ciclosporin had no direct 
effect on endothelial function (p=0.76; n=11) [Figure 3.8c].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: (a) IR caused a reduction in endothelial function (P=0.006; n=11) (b) Administration of 
Ciclosporin around the onset of reperfusion protected against endothelial IR injury in the resistance vessels 
(P=0.44; n=11). (c) Ciclosporin had no effect on endothelial function (P=0.76; n=11). 
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Study n Baseline AUC Post-IR AUC Post-IR AUC (ANCOVA Adjusted) 
IR 11 2.3±0.5 1.4±0.3 1.4±0.2* 
IR+Ciclosporin 11 2.2±0.4 2.1±0.4 2.2±0.3 
 
 
 
Table 3.4: Summary of Baseline and Post-IR dilator response to ACh AUC data (Cohort 2) 
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Figure 3.11: Role of the inhibition of the mPTP in protection against IR-induced endothelial dysfunction in 
resistance vessels. The IR-induced reduction in dilator response to ACh (Post-IR AUC 1.4±0.2 x 104; n=11) was 
prevented by ciclosporin administered around the onset of reperfusion (Post-IR AUC 2.2±0.3 x 104; n=11). Post 
IR values were adjusted for baseline dilator response to ACh AUC (ANCOVA).  
 
 
 
Data are expressed as mean±SEM. Post-IR dilator response to ACh AUC values (x104) were 
adjusted for baseline AUC by ANCOVA (Regression coefficient 0.53±0.12).  
 *P<0.05, IR vs IR+Ciclosporin 
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3.6 Discussion 
This chapter demonstrates that PostC is dependent on KATP channel activity. In 
conduit and resistance vessels, the non-selective KATP channel blocker, 
glibenclamide abolished protection. In contrast, glimepiride, a KATP blocker that is 
selective for non-vascular tissues, had no effect on PostC. Furthermore, this study 
demonstrates that protection by PostC is mimicked by inhibition of the mPTP, as 
administration of the non-specific inhibitor of mPTP – ciclosporin, around the onset 
of reperfusion, protected against endothelial IR injury. 
 
3.6.1 PostC protects against endothelial IR injury 
IR injury to any organ causes damage directly to the tissue parenchyma, but a 
vascular component of IR injury can interfere with reperfusion and so contribute to 
tissue damage. This vascular injury, mainly in the form of endothelial dysfunction, 
has been well described in both animal and human models (see sections 1.3 & 1.6 of 
chapter 1). In the present study I used IR-induced endothelial dysfunction as a 
convenient proxy to explore the mechanism of PostC in humans. As demonstrated 
previously, IR had no effect on vascular smooth muscle in resistance vessels (187, 
261). Also consistent with previous work, results of this chapter demonstrate that 
PostC preserves endothelial function in conduit vessels exposed to IR, and extends 
these findings to the resistance vasculature (124). It is possible that these 
vasculoprotective effects in conduit and resistance vessels contribute to the clinical 
effect of PostC to reduce tissue injury in patients. 
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3.6.2 Mechanisms of protection by PostC 
Studies of the mechanisms of PostC in the mammalian heart have revealed a 
number of themes. There is involvement of endogenous ligands which include 
adenosine, bradykinin and opioids to trigger protection which is then dependent on 
activation of a number of intermediate pathways, including the NO/cGMP pathway, 
reperfusion injury salvage kinases (RISK pathway) and KATP channels. Ultimately, 
modulation of mitochondrial energetics (critical for many types of ischaemic 
protection) seems to be a key aspect of PostC, because inhibition of the 
mitochondrial permeability transition pore (mPTP) at reperfusion mimics PostC (156, 
265). These pathways, identified in animal models, provide opportunities to 
pharmacologically probe the mechanism of PostC in humans.  
 
3.6.3 A role for KATP channels in PostC in humans 
It has previously been shown in humans that KATP channel activation mimics and 
blockade of KATP channels inhibits ischaemic preconditioning in humans (233). The 
results of this chapter demonstrate that glibenclamide (non-selective KATP channel 
blocker) largely abolishes PostC-induced protection against endothelial IR injury, in 
conduit and resistance vessels. These data implicate the KATP channel in the 
mechanism of PostC, and are consistent with animal data (145, 154-156, 266, 267). 
The molecular structure of KATP channels offers an explanation for the differential 
effect of glibenclamide and glimepiride (see section 1.4.3 of chapter 1). KATP 
channels in cardiac and vascular tissue comprise mainly KIR6.2/SUR2A and 
KIR6.1/SUR2B channels respectively, and are more sensitive to non-selective 
blockade by glibenclamide (262, 263). In contrast, glimepiride preferentially blocks 
KIR6.2/SUR1 channels, which predominate in the pancreas. Animal and human 
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studies have demonstrated that glimepiride has fewer cardiac actions compared to 
glibenclamide (262-264, 268, 269). I observed a clear effect of glibenclamide but not 
glimepiride to abolish the protective effects of PostC in both vascular beds studied. 
The results are not easily explained by differences in dose, as the hypoglycaemic 
effect of both drugs was similar (Figure 3.3). Epidemiological studies have not 
consistently identified whether glibenclamide increases the risk of ischaemic tissue 
damage when used to treat diabetes, but the differential effects of KATP channel 
blockers identified in this study provide a theoretical basis for choosing between 
them. Although some studies suggest that glimepiride may induce ischaemic 
protection by other mechanisms, my results do not show this in humans in vivo (270, 
271). 
 
3.6.4 Mimicking PostC by mPTP inhibition at reperfusion 
Although the exact molecular structure of the mPTP is yet to be determined its role 
in cell death after IR injury is well recognised (272).  During ischaemia the mPTP 
remains closed but at reperfusion it opens (32). Opening of the mPTP leads to 
inability of the cells to generate ATP for the repair of damage caused by the Ca2+ 
dependent proteases, nucleases and phospholipases activated during IR injury, a 
process that contributes to cell death (24). 
This chapter demonstrates that the non-specific mPTP inhibitor – ciclosporin 
administered intra-arterially at a dose of 0.6µmol/min around the time of reperfusion 
protects against endothelial IR injury in human forearm resistance vessels. A key 
aspect of the study design was to ensure that ciclosporin was administered close to 
the moment of reperfusion.  The cumulative dose of ciclosporin used was 
comparable to that which achieved a protective effect in similar studies in isolated rat 
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hearts and human atrial tissue (273, 274).  This was in an attempt to limit the intra-
arterial dose of ciclosporin to subsystemic levels and also to avoid higher doses that 
may lead to a reversal of the protective effect (273).  However, experimental 
evidence suggests that mPTP opening can be transient and may not necessarily 
lead to cell death (275, 276). Therefore, a plausible explanation for my results is that 
ciclosporin afforded protection in this model of IR injury by inhibition of long lasting 
mPTP opening.  
Available evidence suggests that PostC induces protection against IR injury by 
modifying early stages of reperfusion; such that a delay in the application of the 
PostC stimulus for as short as 1 minute results in loss of the protection (124). 
Protection against IR injury by pharmacologically inhibiting the mPTP at reperfusion 
suggests this as a possible mechanism of PostC. These data are in agreement with 
animal data in which mPTP inhibitors such as ciclosporin, NIM811, debio-025 and 
sanghliferin A, given at the time of reperfusion after prolonged ischaemia, limited IR 
injury (156, 277, 278). The possibility of a direct effect of ciclosporin on endothelial 
function was considered, but my data show that ciclosporin had no direct effect on 
endothelial function. In a study in patients presenting with acute myocardial 
infarction, ciclosporin administered around the time of reperfusion caused a 
significant reduction of creatine kinase a biochemical marker of myocardial infarct 
size (157). My results provide further evidence that ciclosporin might be exploited as 
an adjuvant during reperfusion therapy in humans. 
 
3.6.5 Conclusion 
In summary, these data provide further support for ischaemic postconditioning as an 
effective protective strategy against IR injury in humans. In addition, an immediate 
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therapeutic implication of my results is that preserving vascular KATP channel activity 
will be necessary to facilitate the development of new treatments, irrespective of 
whether they are based on old or new drugs. Evidence from my study and the study 
in patients presenting with myocardial infarction suggests that inhibition of the mPTP 
to limit IR injury in humans might be clinically useful.   
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Chapter 4 
 
 
 
 
The role of endogenous opioids 
 in the transfer of ischaemic protection by 
remote conditioning stimuli 
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4.1 Introduction 
Ischaemic preconditioning (IPC) protects against damage from ischaemia-
reperfusion (IR) injury. Though first noted to cause localized protection, it is now 
evident that there is a cotemporaneous systemic mechanism that is activated by IPC 
and which causes ischaemic protection in tissues remote from those undergoing 
IPC. Two variants of remote protection have been identified; remote ischaemic 
preconditioning (RIPC), where the preconditioning stimulus is applied before IR 
injury and remote ischaemic postconditioning (RPostC) where the preconditioning 
stimulus is applied during IR injury. The discovery that limb ischaemia activates 
RIPC and RPostC has led to their validation in humans, and a number of clinical 
trials have reported promising biological effects of RIPC in patients (189). 
Understanding the mechanism whereby protection spreads to distant tissues has 
scientific and therapeutic implications. In animals and humans, a neuronal 
mechanism has been proposed, because RIPC-induced protection is abolished in 
the presence of ganglionic blockade (178, 179,187). There is also evidence for 
haematogenous spread of RIPC; ischaemic protection transfers in blood to 
preconditioning-naïve animals (177, 279). In humans, plasma extract obtained after 
activation of RIPC pathways contains a factor that reduces IR injury in vitro (174). 
The identity of the transferable factor(s) remains unknown, though it is opioid-
dependent and crosses species (174, 177, 279). It has not yet been possible to 
demonstrate in humans that there is inter-individual haematogenous spread of 
remote ischaemic protection. This reflects the logistical problems and safety 
concerns of using blood or blood products to transfer protection between individuals. 
However differences between IPC, RIPC and RPostC might enable the question of 
intra-individual haematogenous spread to be addressed. Local protection of IPC is 
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independent of any circulating factor, the key difference in its mechanism compared 
to RIPC (280). In addition, the model of RPostC that I used in this thesis uses a 
remote postconditioning stimulus simultaneous with the ischaemic phase of IR 
injury. The consequence of this is that the injured tissue is isolated from the 
circulation during induction of remote ischaemic protection. This scheduling of 
protective stimulus and ischaemic injury minimises the influence of any circulating 
factor. Therefore, in this chapter I undertook experiments to test the following 
hypotheses in healthy volunteers; 
a. RIPC requires the activation of opioid pathways in vivo and is blocked by the 
opioid antagonist naloxone 
b. IPC and RPostC do not require a circulating factor and are not blocked by 
opioid antagonism  
 
4.2 Methods 
97 studies were performed on 19 healthy non-smoking male volunteers aged 
between 18 and 45 years who were recruited from the University College London 
staff and student community. 9 volunteers participated in the RIPC and RPostC 
studies (cohort 1) while 10 volunteers participated in the IPC studies (cohort 2). FMD 
was used to assess brachial artery endothelial function (section 2.2.1) and 
measurement of plasma beta endorphins was performed by ELISA (section 2.3.1). 
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4.2.1 Induction of IR injury 
IR injury was induced as described in section 2.1.1. 
 
4.2.2 Induction of remote preconditioning 
RIPC was performed as described in section 2.1.4. 
 
4.2.3 Induction of remote postconditioning 
RPostC was performed as described in section 2.1.5. 
 
4.2.4 Induction of ischaemic preconditioning (IPC) 
This was performed as described in section 2.1.2. 
 
4.2.5 Assessment of plasma beta endorphins 
Volunteers were seated comfortably and a 12-cm blood pressure cuff was placed 
around the upper part of the thigh.  A 19G butterfly needle was placed into a vein in 
the upper arm and a second was positioned into a vein in the leg. Blood samples, at 
specific time points (see below) were collected in EDTA tubes that contained 312µl 
aprotinin (0.6 TIU/ml of blood) and centrifuged to obtain plasma. The plasma 
samples were aliquoted and stored at -80°C until laboratory analysis was performed 
(see section 2.3.1).  
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4.3 Experimental protocols   
 
4.3.1 Effect of IR on endothelial function 
To determine the effect of IR on endothelial function (EF), brachial artery FMD was 
assessed before ischaemia (baseline) and at 20 minutes after reperfusion [Figure 
4.1a].  
 
4.3.2 Effect of remote preconditioning on endothelial IR Injury 
FMD was assessed before and after IR but immediately preceded by ArmRIPC and 
LegRIPC to establish that protection against endothelial IR can be achieved by two 
different RIPC stimuli [Figure 4.1b & c]. 
 
4.3.3 Effect of remote postconditioning on endothelial IR Injury 
FMD was assessed before and after IR but during the index ischaemia the RPostC 
stimulus was applied. This was to establish that protection against endothelial IR can 
be achieved by RPostC [Figure 4.1d]. 
 
4.3.4 Effect of ischaemic preconditioning on endothelial IR Injury 
FMD was assessed before and after IR but immediately preceded by local IPC to 
establish that protection against endothelial IR can be achieved by IPC [Figure 4.1e]. 
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b. 
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d. 
                                                                                      
 
 
 
 
e. 
 
 
 
Figure 4.1: Protocols to determine the effect of (a) IR on endothelial function (EF), (b) ArmRIPC on 
endothelial IR injury; (c) LegRIPC on endothelial IR injury; (d) RPostC on endothelial IR injury and (e) IPC on 
endothelial IR injury. 
 
4.3.5 Effect of opioid receptor blockade on RIPC, RPostC and IPC 
The non-selective opioid receptor blocker, naloxone  was administered intravenously 
at a bolus dose of 6mg, then a continuous infusion at a dose of 0.1 mg/min 
throughout the duration of the protective stimulus [Figures 4.2 a - d]. This dose has 
been used in a previous study in patients and was determined by the increase of β-
endorphin in the plasma to levels that indicate effective opioid receptor blockade 
(281). This protocol was to establish the role of opioid receptors in the different 
modalities of ischaemic protection.  
ArmRIPC  
IPC 
RPostC 
EF EF 
 
EF EF 
 
EF EF 
 
EF EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LegRIPC  
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Figure 4.2: Protocols to determine the effect of naloxone on (a) Arm RIPC (b) Leg RIPC (c) RPostC and (d) 
IPC. 
 
 
4.3.6 Effect of naloxone on endothelial IR injury 
Experiments to assess the direct effect of naloxone on endothelial IR injury were 
also performed [Figures 4.3a & b]. 
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Figure 4.3: Protocols to determine the effect of naloxone on endothelial IR injury with (a) IR alone and with 
(b) IR + No RIPC.  
 
 
4.3.7 Effect of remote conditioning stimulus on local production of beta 
endorphins 
Baseline blood samples were obtained from the arm and the leg as described in 
figure 4.4. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Protocol to determine the effect of remote conditioning stimulus on plasma beta 
endorphins. Baseline blood samples were obtained from the arm [1] and the leg [2]. After the cuff was inflated 
for 4.5 minutes a blood sample [3] was collected from the butterfly needle in the leg vein. Immediately after cuff 
deflation (approximately at 5 minutes) a 2nd blood sample [4] was collected from the leg vein. A 3rd blood sample 
[5] was collected just before the end of cycle 1 (before cuff inflation for cycle 2) and this occurred at 
approximately 9.5 minutes.  During cycle 2, blood samples were collected after the cuff had been inflated [6], 
immediately after the cuff deflation [7] and before the end of cycle 2 [8].  Blood samples were collected 5 minutes 
after the remote conditioning stimulus, from the arm [9] and from the leg [10]. 
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4.4 Calculations and Statistical Analysis 
For FMD these are as described in section 2.4. Plasma beta endorphin 
concentrations were measured in ng/ml. In all cases, a value of P<0.05 was 
considered statistically significant. 
 
4.5 Results 
All subjects tolerated the procedure. There were no significant effects on blood 
pressure, heart rate, baseline brachial artery diameter or FMD flow stimulus during 
reactive hyperaemia (Table 4.1). 
 
 
Table 4.1: Summary of blood pressure, heart rate, baseline brachial artery diameter and FMD flow stimulus 
(no units) during reactive hyperaemia. 
 
 
 IR Alone (n=8) IR+ArmRIPC (n=8) IR+RPostC (n=9)  IR+ArmRIPC + 
naloxone (n=9) 
IR+RPostC + 
naloxone (n=8) 
  Pre 
 
Post 
 
Pre 
 
Post 
  
Pre 
 
Post Pre Post    Pre        Post 
SBP  
(mmHg) 108±8 109±8 111±4 112±3 105±3 108±2 111±3 114±4 114±5         110±2 
 
DBP 
(mmHg) 66±5 67±5 60±3 66±1 58±2 60±4 63±3 66±2 66±4         64±3 
HR 
(bpm) 63±4 63±4 60±4 58±4 59±3 64±3 66±3 65±2 63±3         61±2 
Baseline 
arterial 
diameter 
(mm) 
3.9±0.2 3.8±0.2 4.0±0.2 4.0±0.2 3.7±0.1 3.7±0.1 3.9±0.1 3.8±0.1 3.7±0.1     3.8±0.1 
Flow 
Stimulus 9.1±1.1 10.2±1.3 10.3±1.1 10.9±1.4 9.4±0.6 10.6±1.3 10.1±0.4 11.5±0.4 9.3±1.6   10.2 ±1.1 
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4.5.1 Effect of IR on endothelial function 
IR reduced brachial artery FMD (FMD 7.8±0.8% before IR vs 3.6±0.7% post-IR; 
*p<0.0001; paired t test; n=8) [Figures 4.5a & 4.7]. A significant correlation existed 
between baseline and post-IR values for FMD (Pearson’s r=0.5, P<0.001). These 
correlations justified using ANCOVA to adjust post-IR values for differences in 
baseline endothelial function (EF) between the different protocols, so that post-IR EF 
could be directly compared with greater statistical power (Figure 4.7) 
 
4.5.2 Effect of RIPC on endothelial IR injury 
RIPC prevented the IR induced reduction in brachial artery FMD (FMD 7.1±0.5% 
before IR+Arm RIPC vs 6.9±1.0% after IR+Arm RIPC, p=NS; n=8 and FMD 
7.2±0.8% before IR+Leg RIPC vs 7.3±0.7% after IR+LegRIPC, p=NS; n=7) [Figures 
4.5 b & c & 4.7]. 
 
 
4.5.3 Effect of RPostC on endothelial IR injury 
RPostC prevented the IR induced reduction in brachial artery FMD (FMD 6.5±0.8% 
before IR+RPostC vs 6.6±1.0% after IR+RPostC, p=NS; n=7) [Figures 4.5d & 4.7].  
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4.5.4 Role of opioid receptors in protection by RIPC and RPostC 
Naloxone abolished the protection by RIPC (arm or leg) against IR-induced 
endothelial dysfunction in the brachial artery FMD (7.0±0.6% before IR+Arm 
RIPC+naloxone vs 2.8 ± 0.6% after IR+ArmRIPC+naloxone, p<0.001; n=8) and 
6.7±0.7% before IR+Leg RIPC+naloxone  vs 3.0 ± 0.5% after IR+ 
LegRIPC+naloxone, p<0.001; n=6) [Figures 4.6a & b & 4.7].  In contrast, naloxone 
did not affect the protection afforded by RPostC (7.1±0.6% before 
IR+RPostC+naloxone vs. 7.0 ± 0.7% after IR+RPostC+naloxone, p =NS; n=8) 
[Figures 4.6c & 4.7]. 
  
 
 
 
 
 
Figure 4.5: IR reduced endothelial function in the (a) brachial artery (FMD 7.8±0.8% pre-IR versus 
3.6±0.7% post-IR; *P<0.0001; n=8).The IR induced endothelial dysfunction was prevented by (b) ArmRIPC 
(FMD 7.1±0.5% pre- versus 6.9±1.0% post-IR+ArmRIPC; P=NS; n=8),  (c) LegRIPC (FMD 7.2±0.8% pre- 
versus 7.3±0.7% post-IR+LegRIPC; P=NS; n=7) and  (d) RPostC (FMD 6.5±0.8% pre- versus 6.6±1.0% 
post-IR+RPostC; P=NS; n=7).  BL=baseline. 
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Figure 4.7: Role of opioid receptors in protection by RIPC and RPostC in the brachial artery. ArmRIPC 
(post-IR FMD, 6.9±0.9%, n=8), LegRIPC (post-IR FMD, 7.4±0.5%, n=7) and RPostC (post-IR FMD, 7.0±0.7%, 
n=7) prevented IR-induced reduction in FMD. The protective effects of ArmRIPC (post-IR FMD, 3.0±0.4%, n=8) 
and LegRIPC (post-IR FMD, 3.0±0.4%, n=6) were abrogated by systemic naloxone. In contrast, the protective 
effect of RPostC was preserved in the presence of naloxone (post-IR FMD, 6.9±0.5%, n=8).  Post-IR values 
were adjusted for baseline FMD (ANCOVA). 
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Figure 4.6: Naloxone abolished the protective effects of (a) ArmRIPC (FMD 7.0±0.6% pre-IR versus 
2.8±0.8% post-IR; *P<0.001; n=8) and (b) LegRIPC (FMD 6.7±0.7% pre- versus 3.0±0.5% post-
IR+LegRIPC+naloxone; *P<0.001; n=8). Naloxone did not affect the protection afforded by (c) RPostC (FMD 
7.1±0.6% pre- versus 7.0±0.7% post-IR+LegRIPC+naloxone; P=NS; n=8) BL=baseline 
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4.5.5 Role of opioid receptors in protection by IPC 
In the cohort of volunteers that took part in the IPC studies (n=10), IR reduced 
brachial artery FMD (FMD 6.7±0.7% before IR vs 2.5±0.4% after IR, *p<0.0001; 
n=10) (Figure 4.8a). IPC prevented the IR induced reduction in brachial artery FMD 
(FMD 6.3±0.5% before IR+IPC vs 6.5±0.6% after IR+IPC, p=NS; n=10) [Figure 
4.8b]. Naloxone had no effect on protection against IR-induced endothelial 
dysfunction by IPC (6.1±0.4% before IPC + vs. 6.5±0.6% after IPC, p =NS; n =10) 
[Figure 4.8c] 
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Figure 4.8: IR reduced endothelial function in the (a) brachial artery (FMD 6.7±0.7% pre-IR versus 2.5±0.4% 
post-IR; *P<0.0001; n=10).The IR induced endothelial dysfunction was prevented by (b) IPC (FMD 6.3±0.5% pre- 
versus 6.5±0.6% post-IR+IPC; P=NS; n=10).  (c) Naloxone did not affect the protection afforded by IPC (FMD 
6.1±0.4% pre- versus 6.5±0.6% post-IR+IPC; P=NS; n=10) 
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4.5.6 Effect of remote conditioning on beta endorphins  
The concentration of plasma beta endorphins did not change after LegRIPC (p=NS; 
ANOVA; n=6) [Figure 4.9]. 
 
 
 
 
 
 
 
                      
 
 
 
4.6 Discussion 
Results in this chapter demonstrate that naloxone inhibits RIPC-induced endothelial 
protection from IR injury. Naloxone had no effect on other ischaemic conditioning 
stimuli that have little or no requirement for circulating mechanisms to effect 
protection. The most plausible explanation is that opioid antagonism blocks a 
humoral mediator that contributes to the systemic spread of ischaemic protection in 
RIPC, but which is not required in IPC or RPostC.  Control studies confirmed that 
naloxone had no direct effect on the endothelial response to IR injury. 
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Figure 4.9: There was no significant change in plasma beta endorphin concentrations during the remote 
conditioning stimulus comprising 2 leg cycles of 5 minutes ischaemia and 5 minutes reperfusion (p=NS; 
ANOVA; n=6).  
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4.6.1 Effect of opioid antagonism on IPC 
Ischaemic preconditioning represents the best characterised example of hormesis, 
whereby controlled doses of a potentially injurious stimulus (brief periods of 
ischaemia) induce transient protection against a larger toxic dose of the same 
stimulus. IPC induces release of multiple triggers that activate membrane bound 
receptors (94). These in turn stimulate a complex kinase-based mechanism which 
leads to changes in mitochondrial energetics and subsequent tissue protection. The 
human forearm model of IR injury and IPC mimics many of the facets of the 
mechanisms of IR and IPC identified in pre-clinical models. IR injury is dependent on 
endogenous oxidant stress, is reduced by exogenous anti-oxidants, and NO-based 
interventions (41, 282, 283). Activation of IPC requires a threshold stimulus; 
protection requires activation of mitochondrial ATP-sensitive potassium channels 
and is mimicked by inhibition of the mitochondrial permeability transition pore (94). 
Though endogenous opioids have been shown to trigger IPC in some animal 
models, at the systemic dose that was administered in this thesis, there was no 
effect of opioid antagonism to block IPC-induced protection. My observations 
compare with the results of a previous study in isolated rabbit hearts; in which 
naloxone did not inhibit local preconditioning but abolished the protection afforded by 
transfer of an IPC concentrate (280). This research group postulates that ischaemic 
protection by IPC is mediated by multiple, independent or ‘in-parallel’ protective 
mechanisms such that blocking the opioid pathway alone does not affect protection. 
The dose of naloxone I have chosen has been previously demonstrated to inhibit the 
effects of endogenous opioids in humans and increase plasma concentration of 
endorphins via receptor displacement (281). Whether larger doses or co-
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administration with other agents (to target multiple triggers) would be needed to 
block IPC remains to be determined. Therefore, although the present study does not 
rule out a role for endogenous opioids in the mechanism of IPC, it strongly suggests 
that opioids are not necessary to effect IPC in humans in vivo. 
 
4.6.2 Systemic spread of protection in RIPC 
Tissue mechanisms of ischaemic protection by RIPC resemble those of IPC with 
respect to the involvement of triggers, mediators and effectors (see section 1.7.1). 
However the systemic spread of protection from a localised stimulus implies the 
involvement of humoral and/or neuronal mechanisms and evidence for both has 
emerged. Autonomic ganglionic blockade inhibits RIPC in animals and humans (168, 
172,187). However, there is strong evidence that a humoral mechanism can also 
effect systemic protection. Organ denervation does not block RIPC, and there is 
inter-individual transfer of ischaemic protection by blood or blood products (174, 177, 
279, 284, 285). The nature of the active principle in the blood remains uncertain, 
with circumstantial evidence supporting each of adenosine, bradykinin, opioids and 
cannabinoids (286). The relative contribution of the neural and humoral components 
and the degree to which they interact might vary between species and the nature of 
the IR injury and the preconditioning stimulus.  
In a previous study, ganglionic blockade with trimetaphan inhibited the effect of 
RIPC to prevent endothelial IR injury, a finding that supported a neuronal 
mechanism in humans. However a dialysable plasma extract from volunteers in 
whom preconditioning pathways have been activated has been identified that 
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reduces myocardial IR injury in the rat isolated heart (174). The activity of this 
unidentified substance was blocked by naloxone, strongly suggesting that it 
activates opiate receptors. Results in this thesis provide corroborative in vivo 
evidence that RIPC is opioid-dependent. As previously shown, the contrast with IPC 
is best explained by naloxone inhibiting the spread of protection rather than 
interfering with local activation or effector mechanisms, given the similarities of these 
aspects of the mechanism between IPC and RIPC (280). However, these studies do 
not themselves differentiate between an opioid based humoral or neuronal 
mechanism.  
 
4.6.3 Role of opioids in RPostC 
Differences in the scheduling of the conditioning ischaemia between RIPC and 
RPostC provide an opportunity to examine the role of a circulating factor in humans. 
In the RPostC protocol that was used in this thesis, the index ischaemia and 
conditioning ischaemia are co-temporaneous. The corollary of this is that the limb 
undergoing index ischaemia is completely isolated from the circulation during the 
application of the ischaemic preconditioning stimulus on the contra-lateral limb. This 
would be expected to minimise any influence of a blood-borne protective substance, 
but leave neuronal mechanisms intact. RPostC had a similar protective effect to 
RIPC but this was unaffected by naloxone administration. This is strong evidence 
that the opioid component of remote protection requires an intact circulation and is 
humoral rather than neuronal.  
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4.6.4 Relative contribution of neuronal and humoral pathways 
RIPC is sensitive to neuronal or opioid blockade, with inhibition of either pathway 
blocking protection. This could be because the neuronal and humoral pathways are 
arranged in series. An alternative mechanism is that they are parallel pathways and 
each is required to breach a threshold stimulus above which ischaemic protection is 
triggered. The present study provides evidence that the pathways are not simply 
arranged in series, because protection from RPostC (activated principally 
neuronally) persisted after administration of naloxone. It remains to be determined 
how activation of one pathway during RPostC is sufficient to cross a threshold to 
effect remote ischaemic protection, whereas for RIPC both pathways need to be 
activated. One explanation is that the conditioning stimulus of RPostC is closer in 
time to the index injury, and it is possible that the closer in time the protective 
stimulus is to the index ischaemia, the greater is the degree of protection. The 
hypothesis would be that at this earlier timepoint, RPostC crosses a threshold for 
protection.  
 
4.6.5 Beta endorphins in remote conditioning 
The endogenous opioids (endorphins, dynorphins and enkephalins), mediate their 
effects via the activation of the mu-, kappa- and delta – opioid receptors respectively 
(251). In this thesis plasma beta endorphins were assayed as a sensitive marker of 
activation of the endogenous opioid pathway during the remote conditioning 
stimulus. The lack of a significant change in the concentration of plasma beta 
endorphin in response to the conditioning stimulus might possibly be due to absence 
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of a plasma extraction process by acidification to purify the samples. This was based 
on protocols of the KCH laboratory, which does not recommend extraction when 
dealing with relatively small polypeptides such as beta endorphin, because of the 
risk of denaturation. Another possibility is that other endogenous opioids such as the 
enkephalins or dynorphins might have played a more prominent role during the 
remote conditioning stimulus. Further studies will be needed to explore this in more 
detail.   
 
4.6.6 Conclusion 
Results in this chapter provide evidence in vivo for a circulating factor that 
contributes to ischaemic protection in humans. It is sensitive to opioid antagonism 
and may act independently of nervous system control. There is a complex 
interaction between the circulating factor and the nervous system, which is explored 
in more detail in the next chapter. It is possible that the identification of this humoral 
factor will allow supra-physiological activation of ischaemic conditioning pathways, 
with greater potential to reduce IR injury than has been possible to date. 
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Chapter 5 
 
 
 
The role of the neurogenic pathway in  
remote ischaemic protection 
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5.1 Introduction 
Chapter 4 of this thesis described evidence for a circulating opioid pathway in the 
transfer of protection by RIPC. Previous studies in this laboratory have 
demonstrated that complete autonomic blockade using trimetaphan abolished 
protection against endothelial IR injury by early and late RIPC in healthy volunteers 
(187). This builds on data from animal models which have shown that the ganglion 
blocker hexamethonium can block the protective effects of RIPC (178, 179).  
However, available data do not give a clear indication of the relative contribution of 
the neurogenic or humoral pathways in the mediation of protection by a remote 
stimulus. The plausibility of a complex interaction between humoral factors and the 
neurogenic system is highlighted in studies which show that an intact nerve supply is 
essential to facilitate remote protection by circulating factors (175). 
Using an in vivo model of endothelial IR injury I sought to further investigate the role 
of the autonomic pathways in protection by RIPC and RPostC.  In this chapter 
phentolamine and atropine were used as pharmacological probes to determine the 
role of the alpha adrenergic and cholinergic neural pathways respectively.   
 
5.2 Methods 
5.2.1 Subjects 
83 studies were performed on 17 male, healthy, non-smoking volunteers aged 18-45 
years. Cohort 1 (n=10) were recruited for the RIPC protocols and cohort 2 (n=10) 
were recruited for the RPostC studies. Missing data are attributable to the inability of 
some of the participants to complete the protocol which entailed several visits.  
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5.2.2 Assessment of Conduit Vessel Endothelial Function 
Brachial artery flow mediated dilatation (FMD) of the right arm was assessed as 
described in section 2.2.1. 
 
5.2.3 Induction of IR injury 
IR injury was induced as described in section 2.1.1. 
 
5.2.4 Induction of remote preconditioning 
ArmRIPC was performed as described in section 2.1.4. 
 
5.2.5 Induction of remote postconditioning 
RPostC was performed as described in section 2.1.5. 
 
5.3 Experimental Protocols 
5.3.1 Effect of IR on Endothelial Function 
To determine the effect of IR on endothelial function (EF), brachial artery FMD was 
assessed before ischaemia (baseline) and at 20 minutes after reperfusion [Figure 
5.1a].  
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5.3.2 Effect of ischaemic conditioning stimuli on Endothelial IR Injury  
FMD was assessed before and after IR injury + ArmRIPC or RPostC [Figures 5.1b & 
c].  
a.                
 
 
 
b. 
                                                                                                                        
 
 
 
 
 
c. 
                                                                                      
 
 
 
Figure 5.1: Protocols to determine the effect of RIPC and RPostC on endothelial IR. 
 
 
5.3.3 Effect of alpha adrenergic receptor blockade on RIPC and RPostC  
The alpha adrenergic receptor blocker, phentolamine was administered 
intravenously at a dose of 0.2 – 0.7mg/min, as described previously (287). The 
infusion rate for each volunteer was titrated according to the response observed with 
dose increments every 5 minutes as appropriate; the drug was considered to be at 
the effective dose when there was a stable drop of 10mmHg in the systolic arterial 
pressure or a sustained increase of 10 beats per minute in heart rate (287) [Table 
ArmRIPC 
 
EF EF 
 
EF EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
RPostC 
EF EF 
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5.1]. The phentolamine infusion, at the effective dose, was commenced at least 5 
minutes before RIPC and RPostC and was continued through these interventions. 
This was to determine the effect of phentolamine on ArmRIPC and RPostC [Figures 
5.2a and b]. 
 
a.  
                                                                                                                        
 
 
 
 
 
b. 
                                                                                      
 
 
 
Figure 5.2: Protocols to determine the effect of alpha adrenergic blockade on RIPC and RPostC 
 
 Phentolamine effective dose (n=22) 
  Pre                Post 
SBP 
(mmHg) 
 
115±4 119±4 
DBP 
(mmHg) 63±3 68±2 
HR (bpm) 63±3 81±4 
 
Table 5.1: Evidence of the effective dose of phentolamine was a sustained increase in heart rate of >10 
beats per minute above baseline. 
 
ArmRIPC+ phentolamine 
EF EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
RPostC + phentolamine 
EF EF 
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5.3.4 Effect of cholinergic receptor blockade on RIPC and RPostC 
The cholinergic receptor blocker, atropine was administered intravenously at a bolus 
dose of 10mcg/kg. This is a dose that is similar to that in clinical use and has also 
been used previously in healthy volunteer studies (288, 289). Atropine was 
administered 5 minutes before ArmRIPC and RPostC [Figures 5.3a and b]. 
a. 
. 
                                                                                                                        
 
 
 
 
 
 
 
b. 
 
                                                                                      
 
 
 
 
Figure 5.3: Protocols to determine the effect of the cholinergic receptor blockade on (a) RIPC and (b) 
RPostC 
 
5.3.5 Effect of combined alpha adrenergic + cholinergic receptor blockade on 
RIPC 
  
Both phentolamine and atropine were administered, as described above, 
simultaneously [Figure 5.4]. 
EF EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atropine 
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Figure 5.4: Protocol to determine the effect of combined alpha adrenergic and cholinergic receptor blockade 
on RIPC. 
 
5.3.6 Effect of phentolamine and atropine on endothelial IR injury 
Phentolamine or atropine was administered, as described above, to determine the 
effect of administration of phentolamine and atropine on endothelial IR injury 
(Figures 5.5a and b).  
 
a. 
 
 
                                                                                      
 
 
 
b. 
 
                                                                                      
 
 
 
Figure 5.5: Protocols to determine the effect of atropine or phentolamine on endothelial IR injury. 
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5.4 Calculations and Statistical Analysis 
As described in section 2.5 of chapter 2. 
 
5.5 Results 
The studies were generally well tolerated with most volunteers experiencing nasal 
congestion during the phentolamine studies and a dry mouth with atropine studies. 
In two subjects, during phentolamine studies transient episodes of palpitations with 
tachycardia were managed conservatively and the studies were stopped. There 
were no significant confounding effects on blood pressure, heart rate, baseline 
brachial artery diameter or FMD flow stimulus during reactive hyperaemia during 
FMD measurements [Table 5.2].  
 IR Alone (RIPC studies) IR+RIPC IR+RIPC+Phent IR+RPostC+Phent 
 Pre Post Pre Post Pre Post Pre             Post 
SBP 
(mmHg) 113±2 117±2 112±3 116±2 115±2 115±3 111±2        116±2 
DBP 
(mmHg) 65±1 67±2 62±2 64±3 65±3 68±2 70±3           67±4 
HR (bpm) 64±2 63±4 65±3 63±3 65±3 69±6 65±3           69±4 
Baseline arterial 
diameter (mm) 
 
3.9±0.2 3.9±0.2 3.9±0.2 3.9±0.3 3.9±0.2 4.0±0.2 3.9±0.2       4.0±0.3 
Flow 
Stimulus 7.1±1.0 10.2±1.3 8.3±1.1 9.9±1.4 8.4±0.3 9.6±1.1 8.4±0.3      8.8±0.4 
Table 5.2: Summary of blood pressure, heart rate, baseline brachial artery diameter and FMD 
flow stimulus (no units) during reactive hyperaemia. 
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5.5.1 Effect of IR on vascular dilator function 
 
IR reduced brachial artery endothelial dysfunction in the RIPC study (6.4 ± 1.0% 
before IR vs 2.6±1.2 after IR, p<0.0001; paired t test; n=10) [Figures 5.6a & 5.8] and 
RPostC study (6.4±1.1% before IR vs 2.7± 0.8% after IR, p<0.0001; paired t test; 
n=9) [Figures 5.6b & 5.9] A significant correlation existed between baseline and 
post-IR values for FMD in the RIPC studies (Pearson’s r=0.5, P<0.001) and RPostC 
studies (Pearson’s r=0.5, P<0.01). These correlations justified using ANCOVA to 
adjust post-IR values for differences in baseline endothelial function (EF) between 
the different protocols, so that post-IR EF could be directly compared with greater 
statistical power (Figures 5.8 & 5.9) 
 
5.5.2 Effect of RIPC and RPostC on endothelial IR injury 
RIPC (FMD 6.3±0.7% before vs 5.9±0.7% after IR+ RIPC, p = NS; n=8) [Figures 
5.6c & 5.8] and RPostC (FMD 5.8±0.3% before vs 5.5 ± 0.2% after IR+ RPostC, p = 
NS; n=9) [Figures 5.6d & 5.9] protected from endothelial IR injury.  
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5.5.3 Effect of phentolamine on RIPC and RPostC 
Phentolamine had no effect on the RIPC induced protection (FMD 6.8 ±0.7% before 
vs 5.9±0.7% after IR + RIPC + phentolamine, p=NS; n=9) [Figure 5.7a & 5.8] 
whereas the administration of phentolamine abolished the protective action of 
RPostC (FMD 6.0±0.5% before vs 1.8±0.3% after IR + RPostC + phentolamine, 
p<0.0001;n=8)[Figures5.7b&5.9].  
 
 
 
 
 
 
 
Figure 5.7: The administration of phentolamine had no effect of protection against endothelial IR by (a) RIPC 
(FMD 6.8±0.7% pre- versus 5.9±0.7% post-IR+RIPC+Phentolamine; P=NS; n=9) but abolished the protective 
effect of (b) RPostC (FMD 6.0±0.5% pre- versus 1.8±0.3% post-IR+RPostC+Phentolamine; *P<0.0001; n=8). 
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BL IR+RIPC
0
2
4
6
8
10
12
14
c.
FM
D
  (
%
)
BL IR+RPostC
0
2
4
6
8
10
12
14
d.
FM
D
  (
%
)
Figure 5.6: IR reduced endothelial function in the brachial artery in the RIPC study (FMD 6.4±1.0% pre- 
versus 2.6±1.2% post-IR; *P<0.0001; n=10) and RPostC study (FMD 6.4±1.1% pre- versus 2.7±0.8% post-IR; 
*P<0.0001; n=9)  The IR induced endothelial dysfunction was prevented by (b) RIPC (FMD 6.3±0.7% pre- versus 
6.9±1.0% post-IR+RIPC; P=NS;  n=8), and  (c) RPostC (FMD 5.8±0.3% pre- versus 5.5±0.2% post-IR+RPostC; 
P=NS; n=9) BL=baseline 
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Figure 5.8: Effect of phentolamine (Phent) on protection by RIPC in the brachial artery. RIPC prevented IR-
induced reduction in FMD (post-IR FMD, 6.4±0.4%, n=8). The protective effects of RIPC were preserved in the 
presence of systemic phentolamine (post-IR FMD, 6.1±0.5%, n=9). Post-IR values were adjusted for baseline 
FMD (ANCOVA). 
 
 
Figure 5.9: Effect of phentolamine (Phent) on protection by RPostC in the brachial artery. RPostC prevented 
IR-induced reduction in FMD (post-IR FMD, 6.3±0.2%, n=9). The protective effects of RPostC were abrogated by 
systemic phentolamine (post-IR FMD, 2.4±0.3%, n=8. Post-IR values were adjusted for baseline FMD 
(ANCOVA). 
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5.5.4 Effect of atropine on RIPC and RPostC  
The administration of atropine had no effect on protection against endothelial IR 
injury induced by RIPC (FMD 4.4±0.4% before vs 4.2±0.4% after IR + RIPC + 
atropine, p=NS; n=8) [Figure 5.10a] or by RPostC (FMD 4.0±0.7% before vs 
3.8±0.8% after IR + RPostC + atropine, p=NS; n=6) [Figure 5.10b]. 
 
 
 
 
 
 
 
 
 
5.5.5 Effect of phentolamine + atropine on RIPC  
RIPC induced protection against endothelial IR injury was not significantly affected 
by the administration of the combination of phentolamine and atropine (FMD 5.0±0.8 
% before vs 4.1±0.7% after IR + RIPC + phentolamine + atropine, p=NS; n=7) 
[Figure 5.11]. 
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Figure 5.10: The administration of atropine had no effect of protection against endothelial IR by (a) 
RIPC (FMD 4.4±0.4% pre- versus 4.2±0.4% post-IR+RIPC+Atropine; P=NS; n=8) or (b) RPostC RIPC (FMD 
4.0±0.7% pre- versus 3.8±0.8% post-IR+RIPC+Atropine; P=NS; n=6). BL=baseline 
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5.5.6 Effect of phentolamine and atropine on endothelial IR injury 
Neither Phentolamine nor atropine, administered during a sham RPostC stimulus, 
had any effect on the endothelial response to IR injury (FMD 7.0±0.7% before vs 
3.2±0.3% after IR + shamRPostC+ phentolamine; p<0.001; n=5) [Figure 5.12a] and 
(FMD 5.4±1.0% before vs 3.3 ±1.0% after IR + No RPostC+ atropine; p<0.05; n=4) 
[Figure 5.12b] 
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Figure 5.11: The administration of phentolamine+atropine did not affect protection conferred by RIPC (FMD 
5.0±0.8% pre- versus 4.1±0.7% post-IR+RIPC+Atropine+Phentolamine; P=NS; n=7). BL=baseline 
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Figure 5.12: Endothelial response to IR was not affected by (a) Phentolamine (FMD 7.0±0.7% pre- versus 
3.2±0.3% post-IR+Phentolamine; *P<0.001; n=5) or (b) atropine (FMD 5.4±1.0% pre- versus 3.3±1.0% post-
IR+Atropine *P<0.05; n=4). BL=baseline 
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5.6 Discussion 
This study demonstrates, for the first time in humans, that phentolamine inhibits 
RPostC-induced protection against IR injury. However, phentolamine had no effect 
on RIPC. These results suggest a significant contribution of the alpha adrenergic 
pathway in mediation of protection by RPostC. Furthermore, this study demonstrates 
that atropine had no effect on the protection by RIPC or RPostC, a suggestion that 
the cholinergic pathway plays little role in the mediation of a remote protective 
stimulus.  
   
5.6.1 RPostC is blocked by systemic adrenergic blockade  
Systemic phentolamine administered at a dose that caused detectable adrenergic 
blockade abolished the effect of RPostC to protect remote endothelium from IR 
injury, whereas atropine had no effect. These data implicate the adrenergic but not 
the cholinergic component of the autonomic nervous system in the reflex spread of 
ischaemic protection elicited by RPostC. However it is not possible to be certain that 
a larger dose of atropine might have had an inhibitory effect. Neither atropine nor 
phentolamine affected the endothelial response to IR injury, so the effect of 
phentolamine was unlikely to be explained by a direct effect to exacerbate IR injury 
(although the sample sizes for these studies were small and limit the robustness of 
these conclusions).  
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5.6.2 Relative contribution of neuronal and haematogenous transfer of 
protection by RPostC  
In chapter 4, I presented evidence that a circulating factor contributed to the 
systemic protection that was triggered by RIPC, and likely activated opioid 
pathways. I hypothesised that a haematogenous factor would not contribute to IPC 
(protection was exclusively activated by local pathways) or RPostC (where the 
ischaemic conditioning stimulus activated systemic pathways in a limb that was 
isolated from the circulation). The data on the effects of naloxone were consistent 
with this hypothesis. The corollary was that RPostC could only cause remote 
protection by neuronal pathways. The adrenergic and cholinergic components of the 
autonomic nervous system were rational candidates based on the known 
involvement of the autonomic nervous system in RIPC, and the established role of 
acetylcholine and noradrenaline as triggers of preconditioning in many tissues.  My 
results suggest a pivotal role for the alpha adrenergic receptors in the transfer of 
protection by RPostC by the autonomic nervous system. These results also support 
my conclusion in chapter 4 that the neuronal and humoral pathways probably act in 
parallel rather than simply in series. Both will be activated by the RPostC stimulus, 
but it is only by blocking the neuronal component that it is possible to inhibit RPostC. 
Were the pathways arranged as a single neuro-hormonal mechanism sequential 
mechanism, blockade of one would necessarily inhibit the entire pathway. Indeed if 
this were the case, then RPostC would probably not cause any protection, as my 
data suggest that regardless of the activation of a humoral pathway, it has an 
insufficient biological effect to contribute to ischaemic protection. 
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5.6.3 Interaction between the neural and humoral pathways in RIPC 
Loukogeorgakis et al have previously demonstrated, using a human in vivo model of 
IR injury, that complete autonomic blockade using trimethaphan abolished the RIPC 
induced protection against endothelial IR injury (187). Data in this chapter show that 
the combined effects of alpha adrenergic and cholinergic receptor blockade, by the 
combined administration of phentolamine and atropine, were insufficient to block the 
protective effects of RIPC. This may highlight the unrecognised importance of other 
components of the autonomic nervous system in order to achieve a threshold 
stimulus for RIPC to occur. It is possible that the dose of atropine was too low, or 
that there is a requirement for beta adrenergic blockade. These possibilities will 
require additional study, and it is a weakness of this chapter that these data have not 
been included. There is also the possibility in the study by Loukogeorgakis and 
colleagues that the trimetaphan had off target effects which might have affected 
endothelial function and contributed to protection. However if it is accepted that 
ganglionic blockade effects a more complete autonomic blockade than I have 
achieved in this chapter, then it seems likely that a neuro-humoral reflex accounts 
for the spread of ischaemic protection by RIPC. Given that identical stimuli effect 
RIPC and RPostC, the conclusions drawn about RPostC imply that the neuro-
humoral pathways that underpin the systemic protection of RIPC operate in parallel 
and both contribute to the crossing of a threshold of protection.   
 
5.6.5 Conclusion  
Results in this chapter highlight that the alpha adrenergic autonomic pathway plays 
a role in facilitating RPostC but not RIPC. The cholinergic pathway does not seem to 
be implicated in effecting protection by either RPostC or RIPC. More studies are 
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required to elucidate the role of other components of the autonomic pathway such as 
the beta adrenoceptor pathway and also to determine the relative contribution of 
each of the different pathways (neurogenic or humoral) to remote protection. 
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Chapter 6 
 
The role of inorganic nitrates in  
protection against endothelial  
ischaemia reperfusion injury 
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6.1 Introduction 
Vascular endothelial cells are susceptible to the effects of IR injury and this manifest 
as a measurable endothelial dysfunction (see section 1.5.3). Invariably this affects 
the endothelial production of NO via endothelial NO synthase (eNOS).  NO has been 
implicated in the protective effect of the various interventions against IR injury that 
exist to date (290). There is evidence that an increase in nitric oxide (NO) 
bioavailability, via a complex signalling pathway involving cyclic GMP and various 
protein kinases, results in a reduction in deleterious intracellular processes such as 
calcium overload, mitochondrial permeability transition pore opening and increased 
production of reactive oxygen species (290). This promotes cellular cytoprotection 
and tissue salvage which is the ultimate goal in protection against IR injury. 
Emerging data indicate that inorganic nitrates and nitrites, previously considered to 
be inert end products of NO metabolism, provide a source of NO for cellular 
processes under hypoxic and acidotic conditions, such as during IR injury, when 
NOS becomes dysfunctional (see section 1.10 of chapter 1). The implication is that 
endogenous nitrite and nitrate stores act as a backup source of NO which may be 
beneficial during IR injury. 
Vegetables including beetroot contain a large amount of inorganic nitrate which is 
thought to play a significant role in their potential health benefits (291-293).Once 
ingested the inorganic nitrate is rapidly absorbed via the stomach and a proportion of 
it enters the enterosalivary circulation where it is recycled into NO via reduction to 
nitrite (see section 1.10.2 of chapter 1). The nitrate-nitrite dependent NO generation 
might achieve prominence during hypoxic or ischaemic conditions, such that their 
reduction to NO occurs when NOS–dependent NO synthesis is impaired (196).  This 
process of increasing the bioavailability of NO under ‘stress’ is thought to be the 
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mechanism underlying protection against IR injury by inorganic nitrates and nitrites 
as demonstrated in animal models (196, 294). 
Oral ingestion of inorganic nitrates produces a dose-dependent increase in nitrite 
and NO production in the circulation (202, 203, 217). This might enable the 
therapeutic potential of nitrates to be exploited as a storage pool for nitrite and NO 
generation given their longer half-lives. Based on this I sought to determine the role 
of oral inorganic nitrates in the form of beetroot juice and postassium nitrate (KNO3) 
in protection against endothelial IR injury in the human in vivo model.  
 
 
6.2. Methods 
 
6.2.1 Subjects 
Studies were performed on healthy, non-smoking volunteers, aged 18-45 years.  In 
study one (beetroot 500ml), 20 studies were performed on 10 volunteers and in 
study two (beetroot 250ml & KNO3), 49 studies were performed in 13 volunteers. All 
studies repeated in same volunteers were at least 7 days apart and were an open-
label crossover design for beetroot juice studies and double-blind crossover design 
for potassium nitrate studies.  
 
6.2.2 Assessment of conduit vessel endothelial function 
Brachial artery flow mediated dilatation (FMD) of the right arm was assessed, as 
described in section 2.2.1. 
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6.2.3 Induction of IR injury 
IR injury was induced as described in section 2.1.1. 
 
6.2.4 Determination of plasma nitrite and nitrate concentration  
 
6.2.4.1 Blood samples 
A 19‐gauge butterfly needle, with extension set, was inserted prior to capsule or 
juice ingestion. The blood samples obtained were prepared as described in section 
2.3.2.2. 
 
6.2.4.2 Chemiluminescence 
Plasma nitrite and nitrate concentrations were determined by chemiluminescence as 
described in section 2.3.2.1.  
 
6.3 Experimental protocols 
 
6.3.1 Effect of IR on endothelial function 
To determine the effect of IR on endothelial function (EF), brachial artery FMD 
(Figure 6.1a) was assessed before ischaemia (baseline) and at 20 minutes after 
reperfusion.  
               
 
Figure 6.1a: Protocol to determine the effect of IR on endothelial function 
EF EF 
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6.3.2 Effect of 500ml beetroot juice on endothelial IR injury 
To determine the effect of beetroot juice (Planet Organic®) on endothelial IR injury, 
healthy volunteers were randomised to 500ml of beetroot juice 2 hours before IR or 
no treatment before IR. Subjects underwent the IR injury protocol after beetroot juice 
or no treatment, with both protocols being at least 7 days apart (Figure 6.1b) 
 
 
 
 
 500ml Beetroot juice 2 hours before  
 
Figure 6.1b: Effect of 500ml beetroot juice on endothelial IR Injury 
 
 
6.3.3 Effect of KNO3 on endothelial IR injury 
 
 
To determine the effect of KNO3 (Martindale Pharmaceuticals) on endothelial IR 
injury, healthy volunteers were randomised in a double-blind crossover design to 
receive either 24 mmol of KNO3 or KCl tablets with 500ml of water (Figure 6.1c). 
 
 
 
  
KNO3 1.5 hours before  
 
                
 
 
 
 
      KCl 1.5 hours before 
 
 
Figure 6.1c: Effect of KNO3 on endothelial IR injury 
EF EF 
 
EF EF 
 
EF EF 
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6.3.4 Dose-dependent effect of beetroot juice on endothelial IR injury 
 
 
To determine the effect of beetroot juice containing a lower dose of nitrate (5.5mmol) 
on endothelial IR injury, healthy volunteers received 250ml of beetroot juice (James 
White Drinks Ltd) 1.5 hours before IR or 250ml of water (Figure 6.1d). 
 
 
 
 
 
      250ml Beetroot juice or 250ml water 1.5 hours before 
 
 
Figure 6.1d: Effect of 250ml of beetroot juice on endothelial IR injury 
 
 
6.3.5 Blood sampling for nitrate and nitrite concentration  
 
 
To determine the change in nitrate and nitrite concentrations in plasma after KNO3, 
blood samples were obtained at baseline; then after KNO3 every 30 minutes up to 3 
hours. 
 
6.4 Calculations and Statistical Analysis 
See section 2.5 of chapter 2. 
 
6.5 Results 
The studies were well tolerated with beeturia and red stools as expected adverse 
effects. However one subject developed mild symptoms of gastritis which was 
associated with the potassium chloride capsules (on unblinding). This participant 
EF EF 
 
 159 
was managed conservatively with antacids and withdrawn from the study. The mean 
nitrate concentration was 45.0±2.6mmol/L in the 500ml beetroot juice and 
22.4±3.8mmol/L in the 250ml beetroot juice. The nitrite concentration in both 
volumes of beetroot juice was <50nmol/L.  
 
6.5.1 Study 1 
 
 
6.5.1.1 Effect of IR on endothelial function 
 
IR reduced brachial artery FMD (7.5±0.9% before IR vs 3.1±0.4% after IR, 
p<0.0001; n=10) [Figure 6.2a].  
 
6.5.1.2 Effect of beetroot juice on endothelial IR injury 
500ml beetroot juice prevented IR induced endothelial dysfunction (FMD 6.8±1.0 % 
before IR + BJ 500 vs 5.5±1.0 after IR + BJ 500, p<0.001; n=10) [Figure 6.2a & b]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Effect of beetroot juice (500ml) on endothelial IR injury 
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6.5.2 Study 2 
 
6.5.2.1 Effect of IR on endothelial function 
IR reduced brachial artery FMD (10.3 ±1.0% before IR vs 4.9±0.8% after IR, 
p<0001; paired t test; n=12) [Figures 6.3a & 6.4]. A significant correlation existed 
between baseline and post-IR values for FMD (Pearson’s r=0.7, P<0.0001).These 
correlations justified using ANCOVA to adjust post-IR values for differences in 
baseline endothelial function (EF) between the protocols, so that post-IR EF could 
be directly compared with greater statistical power [Table 6.1] 
 
6.5.2.2 Effect of KNO3 on endothelial IR injury 
KNO3 prevented the IR induced endothelial dysfunction (FMD 11.6±1.2% before IR + 
KNO3 vs 10.2 ±1.1% after IR + KNO3, p=NS; n=.12) [Figures 6.3b & 6.4] whereas 
there was no protection against endothelial IR injury with KCl (FMD 12.1±1.6% 
before IR + KCl vs 7.7±1.0% after IR + KCl, p<0.001; n=12) [Figures 6.3c & Figure 
6.4]  
 
6.5.4 Effect of lower dose beetroot juice derived nitrate  
The lower dose of beetroot derived nitrate (250ml) also reduced the IR induced 
endothelial dysfunction FMD (11.0 ±1.2% before IR + BJ 250 vs 10.7±1.2% after IR 
+ BJ 250, p=NS; n=12) [Figures 6.3d & 6.4]. 
 
 
 
 
 161 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Effect of (b) KNO3, (c) KCl and (d) 250ml of beetroot juice on (a) endothelial IR injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Effect of KNO3 and 250ml of beetroot juice on endothelial IR injury. Both KNO3 (post-IR FMD, 
8.0±0.8%, n=12) and 250ml of beetroot juice (post-IR FMD 8.8.±1.0%, n=12) prevented IR-induced reduction in 
FMD. KCl (post-IR FMD, 5.3±0.5%, n=12) did not protect against IR induced endothelial dysfunction. Post-IR 
values were adjusted for baseline FMD (ANCOVA). 
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Table 6.1: Summary of baseline and Post-IR FMD data 
 
6.5.6 Circulating nitrate and nitrite concentration after oral nitrate load  
Ingestion of 250ml of beetroot juice (5.5mmol nitrate) or KNO3 capsules (24mmol 
nitrate) increased the circulating plasma nitrate concentration within 30 minutes and 
this peaked at 3 hours [Figure 6.5a & b]. The rise in plasma nitrite concentration was 
more modest with significantly elevated levels first evident at 1.5 hours and peaking 
at 2.5 hours [Figure 6.5c and d]. 
 
 
 
 
 
 
 
Study n 
Baseline 
FMD 
Post-IR 
FMD 
Post-IR 
 FMD (ANCOVA Adjusted) 
IR 12  10.3 ±1.0 % 4.9±0.8% 3.4.±0.4* 
IR+KNO3 12 11.6±1.2% 10.2 ±1.1% 8.0±0.8† 
IR+KCL 12 12.1±1.6% 7.7±1.0% 5.3±0.5‡ 
IR+BJ250 12 11.0 ±1.2%  
 
 
10.7±1.2% 8.8.±1.1 
Data are expressed as mean±SEM. Post-IR FMD values were adjusted for baseline FMD by 
ANCOVA (Regression coefficient 0.56±0.13). For comparisons between the 4 groups, P values by 
ANCOVA were Scheffé adjusted. 
*P<0.001, IR vs IR+KNO3 and IR+BJ250  
†P<0.05, IR+ KNO3 vs IR+KCL 
‡P<0.01, IR+BJ250 vs IR+KCL 
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Figure 6.5: Effect of oral nitrate load on plasma nitrate and nitrite compared with KCl. 250ml beetroot juice 
(5mmol nitrate) elevated nitrate and nitrite levels [(a) &(c)]. Similarly, KNO3 (24mmol nitrate) elevated plasma 
nitrate and nitrite [(b) & (d)]. In contrast, KCl had no significant effect on plasma nitrate or nitrite (unfilled data 
points).  Data are expressed as mean SEM of n=9. Significance shown for comparisons as §§§ P<0.0001 for 2-
way ANOVA and *** P<0.001 or **P<0.01 for Bonferroni post hoc tests. 
 
 
 
6.6 Discussion  
Results in this chapter demonstrate, for the first time in humans, that oral inorganic 
nitrate, in the form of beetroot juice or KNO3 capsules, protects against endothelial 
IR injury. Notably this protection was not evident after ingestion of KCL capsules 
which negates potential confounding protective effects of K+. Both beetroot juice and 
KNO3 capsules resulted in increases in plasma nitrate and nitrite indicating that the 
endogenous handling of oral inorganic nitrate is the same whether the source is a 
nitrate salt or the diet. 
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6.6.1 Plasma nitrate and nitrite concentrations after an oral nitrate load 
The exact mechanism by which vegetable-rich diets confer protection against 
cardiovascular disease remains uncertain. However the recent suggestions that their 
beneficial effects are as a result of nitrate/nitrite derived NO has generated further 
interest.  
My results indicate that an oral nitrate load (beetroot juice or KNO3) administered 
before IR produced a rapid (within 30 minutes) rise in circulating plasma nitrate 
concentration while the plasma nitrite concentration showed a more gradual rise with 
significant elevation in concentration at 1.5 hours.  The important finding with respect 
to IR injury was that the elevated nitrate and nitrite concentrations were sustained 
beyond the onset of reperfusion, therefore providing the necessary substrate for NO 
generation. A potential explanation for this time lag between the plasma nitrate and 
nitrite peaks is the endogenous production of nitrites which is facilitated by the 
enterosalivary circuit. This is corroborated by the observation that interruption of this 
circuit, by avoidance of swallowing, blocks the increase in plasma nitrite but has no 
effect on plasma nitrate (202). In addition, beetroot juice contained large amounts of 
nitrate but undetectable levels of nitrite. The reduction of nitrite to NO is thought to 
be facilitated by enzymes (predominantly xanthine oxidoreductase) or 
deoxyhaemoglobin, activities of which are enhanced during ischaemic conditions 
(198, 200, 201).   
Bryan et al showed that nitrate supplementation in the drinking water of mice for 7 
days, which also protected against the damaging effects of a myocardial IR injury, 
was associated with higher steady state plasma and heart nitrite levels (217). 
Conversely, this group observed that feeding mice with a low nitrite/nitrate diet for 
the same period of time, resulted in reduced levels of plasma and myocardial nitrite 
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concentration and the protection against IR injury was lost. The acute rise in plasma 
nitrite concentration I observed is consistent with results from other human studies 
and is associated with nitrate accumulation in saliva and plasma (202, 203).  
 
6.6.2 Oral inorganic nitrate and ischaemic protection 
The early phase of reperfusion is critical in the mediation of IR injury, presenting an 
immediate therapeutic window of opportunity.  My results indicate that oral inorganic 
nitrate in the form of beetroot juice and potassium nitrate tablets, led to a reduction 
in endothelial IR injury. Notably the early phase of reperfusion corresponded with 
elevated plasma concentrations of nitrate and nitrite. I did not observe such an effect 
with my volume control (water) or potassium control (potassium chloride tablets) 
interventions, which strongly suggest that the oral nitrate load was responsible for 
these biological effects. The quantity of nitrite in the diet is limited and the half-life 
short (see section 1.10.3 of chapter 1); therefore there is a need for further 
investigation into the benefits which might be derived from oral inorganic nitrate in 
whatever form.  
 
6.6.3 Clinical perspective 
Contributing to an increase in NO bioavailability appears to be the fundamental 
principle underlying the therapeutic use of oral inorganic nitrates in protection 
against IR injury.  Organic nitrates, such as nitroglycerin (GTN) or isosorbide 
mononitrate, are widely used in clinical practice for the management of heart failure 
or relief of angina and cause rapid generation of NO in vascular smooth muscle.  
This can generate profound vasodilatation which might cause significant 
hypotension and limit their use. Another significant problem with the use of organic 
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nitrates is the development of tolerance. Although the exact mechanism of nitrate 
intolerance is not clear, increased formation of reactive oxygen species have been 
implicated (221, 295). An additional advantage of inorganic nitrates over the organic 
nitrates is that their bioactivation to NO is pH- and pO2- dependent such that 
therapeutic effects are localised to the ischaemic tissue without an unwanted 
generalised effect. 
 
6.6.4 Conclusion  
Inorganic nitrate and nitrite biology has received a considerable amount of research 
interest particularly in relation to its contribution to endogenous NO production and 
protection against IR injury. A parallel study by some of my research collaborators 
also demonstrates effects of oral inorganic nitrates in BP reduction. Further efforts to 
harness the full potential of this area of research should be in the form of well 
designed clinical trials. This will enable us build on the very promising preliminary 
data in this thesis and might enable the exploitation of oral nitrate supplementation in 
the acute or chronic ischaemic setting.   
 
 
 
 
 
 
 
 
 
 167 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 
 
Summary and Conclusions 
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In this thesis, I investigated the mechanisms of ischaemic protective phenomena 
(IPC, PostC, RIPC, RPostC) using a human in vivo model of endothelial IR injury in 
the forearm. I utilised pharmacological probes to investigate the role of a) KATP 
channels and the mPTP in PostC; b) the opioid pathway in remote conditioning; and 
c) components of the autonomic nervous system (alpha adrenergic and cholinergic) 
in remote conditioning. I also determined whether oral inorganic nitrates (beetroot 
juice and KNO3) protected against endothelial IR injury in humans. 
 
7.1 Mechanisms of postconditioning 
In chapter 3, I demonstrated that PostC protects against endothelial IR injury in 
humans in two vascular beds (resistance and conduit vessels). This provides more 
data in support of PostC as a valid therapeutic intervention aimed at reducing IR 
injury in humans. Furthermore, data in this thesis suggest that the mPTP is involved 
in the mediation of protection by PostC as ciclosporin, administered around the 
onset of reperfusion, mimicked the protective effect of PostC. This is consistent with 
data that showed cardioprotection from ciclosporin administered around the time of 
percutaneous coronary intervention in patients presenting with acute myocardial 
infarction (157). An obvious therapeutic implication is pharmacological 
postconditioning with ciclosporin, a drug with a long term safety profile. This might 
enable the therapeutic benefits of ischaemic PostC to be derived whilst avoiding the 
uncertainties of safety and feasibility of the technique.  
Results from Chapter 3 also highlight a role for KATP channels in the mechanism of 
PostC. This was evident from studies which showed that glibenclamide a non-
selective KATP channel blocker abolished the protective effects of PostC against 
endothelial IR injury. However with the pancreas-selective KATP channel blocker, 
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glimepiride, protection by PostC was preserved. KATP channel blockers are widely 
used in clinical practice for the treatment of Type 2 Diabetes. Diabetic patients are at 
an increased risk of cardiovascular events and are more likely to benefit from 
protective phenomena such as PostC. The differential effects of subtype specific 
KATP channel blocker perhaps need to be considered when using these drugs in this 
patient cohort.  
 
7.1.1 Future work 
Translation of the above findings will require clinical trials to determine the optimal 
dose of ciclosporin, as preclinical studies indicate that high dose may actually 
exacerbate IR injury (273). Robust trials with appropriate endpoints should be aimed 
at validating the protective effect of ciclosporin during IR injury and determining the 
differential effects of KATP channel blockers on protective strategies. Such trials will 
not be trivial because they will need to be large and are unlikely to be sponsored by 
the pharmaceutical industry. Epidemiological data from various sources might also 
provide complementary information on cardiovascular outcomes in patients on 
ciclosporin and KATP channel blockers. 
 
7.2 Mechanisms of transfer of protection by remote conditioning 
Data from chapter 4 of this thesis highlight a role for the opioid receptor pathway in 
RIPC. The evidence for this is that non selective opioid receptor blocker, naloxone, 
abolished protection afforded by RIPC. In contrast, protection by IPC was not 
affected by naloxone.  
These results provide a further suggestion that endogenous opioids play a 
prominent role in the transfer of protection from a remote site during RIPC rather 
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than for local protection. Furthermore, the data also indicate that RPostC protected 
against endothelial IR injury and this protection was preserved in the presence of 
naloxone suggesting a less significant role for the opioid pathway in RPostC.   
Experiments in Chapter 5 demonstrate that protection by RPostC is lost when the 
alpha adrenoceptor blocker, phentolamine, was co-administered while protection by 
RIPC was unaffected. This suggests that alpha adrenergic component of the 
autonomic nervous system (ANS) contributes significantly to protection by RPostC. 
My results also show that blockade of the cholinergic component using atropine did 
not affect protection by RIPC or RPostC. This suggests that the cholinergic 
component of the autonomic nervous system is of limited importance during RIPC or 
RPostC. However, previous studies in this laboratory show that complete autonomic 
blockade with trimetaphan abolished protection by RIPC (187). A speculation is that 
in addition to the activation of opioid pathway RIPC depends on a component of the 
autonomic nervous system to cross a threshold of protection. 
The main difference between RIPC and RPostC is in the timing of the application of 
the stimulus in relation to IR. A plausible mechanism of the mode of transfer of 
protection is that the two pathways (neurogenic and humoral) act synergistically in 
parallel, with the autonomic pathway providing an initial predominant stimulus which 
rises above a threshold for protection for a limited period of time during RPostC. As 
time elapses the humoral pathway becomes the predominant stimulus and reaches 
threshold, responsible for protection by RIPC.    
 
7.2.1 Future work 
 
Further studies in order to probe the mechanisms of transfer of protection by remote 
conditioning are essential. Mechanistic studies should aim to determine the role of 
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other humoral factors such as bradykinin, hypoxic inducible factor (HIF) and 
adenosine in the transfer of protection by a remote protective stimulus. Assessing 
the role of the beta adrenoceptor component of the ANS in facilitating remote 
protection is also appropriate. Information on the time course of transfer of protection 
via the neurogenic and humoral pathways will enable an understanding of their 
interaction and relative contribution to remote ischaemic protection. This might 
enable full utilisation of this form of ischaemic protection. 
 
7.3 Oral inorganic nitrates in protection against IR injury 
Studies in chapter 6 focused on the role of oral inorganic nitrates in protection 
against endothelial IR injury. Results suggest that oral inorganic nitrates in the form 
of beetroot juice and potassium nitrate capsules provide protection against 
endothelial IR injury. These data build on previous data which until now have been 
based on animal models of IR injury. The L-arginine-NOS system is a major source 
of NO and is critical in maintaining cardiovascular homeostasis. An important 
advance, with potential therapeutic application, is in the recognition of alternative NO 
generation via the nitrate and nitrite (NOS independent) pathways, during conditions 
associated with dysfunction of the NOS dependent pathway, as in IR injury.  
 
7.3.1 Future work  
Further studies using other human models of IR injury are required to characterise 
the protective role of NOS independent pathway and validate this potential 
therapeutic target.  
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7.4 Conclusion  
This translational research project has been performed to obtain mechanistic 
information on aspects of ischaemic protection in humans.  The ultimate goal is to 
identify therapeutic targets which can be developed for clinical application. The 
persisting gaps in knowledge necessitate further research. 
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